Background: TSPO is an 18kDa mitochondrial protein of indeterminate function. Its high expression on macrophages has led to its use as an imaging marker in inflammatory disease. Due to the critical role of macrophages in arthritis pathogenesis, TSPO may be useful as a marker of disease activity in inflammatory arthritis. Here, we demonstrate the TSPO PET (positron emission tomography) tracer [ 11 C]PBR28 can detect and quantify synovitis. Through synovial histology, we demonstrate TSPO expression in tissue correlates with synovitis severity and macrophage prevalence. Little is known about the expression of TSPO in cells that constitute synovium. We present in vitro work demonstrating activated macrophages and fibroblasts highly express TSPO, hence may account for majority of tracer signal in joints imaged with TSPO targeted PET. Methods: Ten patients with inflammatory arthritis (5 males, 5 females, average age 53), and four healthy controls were included in this study. All patients underwent imaging of both knees with the TSPO-specific PET tracer [ 11 C]PBR28, and synovial biopsy of one knee within seven days. Healthy synovium was obtained by arthroscopic biopsy of patients undergoing knee surgery for ligament injury. For in vitro study, monocytes and lymphocytes were isolated from synovial fluid of arthritis patients. Monocytes were differentiated to macrophages. Lymphocytes were activated using PMA and ionomycin. RA fibroblastlike synoviocytes (FLS) were obtained from digestion of tissue from joint replacement surgery, and stimulated with TNF-a or IL-1b for 24 hours. Results: [ 11 C]PBR28 tracer uptake was highest in joints most inflamed on clinical examination. Joints of arthritic patients that were noninflamed on clinical examination had a higher uptake of TSPO tracer than healthy control joints. Immunohistochemistry of synovial biopsies demonstrated, co-staining of TSPO with macrophage markers CD68 and CD163, and the fibroblast activation marker podoplanin. TSPO, CD68 and CD163 staining positively correlated with tracer uptake. In vitro studies demonstrated least mRNA expression of TSPO in monocytes and lymphocytes (fold change 13 and 1, respectively), with most in M-CSF macrophages (60.7AE2.38) and FLS stimulated with TNF-a or . Western blot demonstrates upregulation of TSPO protein on macrophages and activated FLS compared to monocytes and unstimulated FLS respectively. In contrast, expression of TSPO on unstimulated and stimulated lymphocytes did not change significantly at mRNA or protein level.
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Conclusion: The TSPO tracer [
11 C]PBR28 is capable of quantifying and detecting synovitis. Through TSPO staining of biopsy samples, tracer uptake is likely to reflect TSPO expression in the synovium, rather than any confounding factors, and TSPO co-stains with known macrophage markers. TSPO tracer uptake in synovium may not reflect macrophage infiltration alone; histology and in vitro data suggest that TSPO expression in synovium may also reflect the presence of activated FLS, another cell group with an essential role in the generation of synovitis. Disclosure statement: The authors have declared no conflicts of interest. Background: Neutrophil dysregulation is important in the pathology of various inflammatory and autoimmune rheumatic diseases (ARD), including RA, SLE and APS. Various environmental factors can modulate neutrophil function, such as inflammatory cytokines, circulating IgG and localized tissue hypoxia (0.5 2.7% O 2 ), such as occurs in inflamed or ischaemic tissues. Neutrophil activation can result in the release of a meshwork of chromatin fibers decorated with antimicrobial proteins, called neutrophil extracellular traps (NETs), which is dysregulated in various ARDs. Integrin activation modulates several aspects of neutrophil function including: adhesion, cytokine production, reactive oxygen species (ROS) generation and NETosis. Previously, we have shown that hypoxia modulates: adhesion molecule expression in HUVEC, neutrophil adherence to HUVEC monolayers and NET release. Therefore, we investigated the effects of hypoxia upon neutrophil integrin expression, adhesion to immobilized ligands and endothelial cells and trans-endothelial migration (TEM) to better understand the effects of hypoxia upon the stages preceding NETosis. Methods: Neutrophils were isolated from whole blood donated by healthy volunteers and cultured under normoxia (21% O 2 ) or hypoxia (1% O 2 ). NETosis was visualized by immunofluorescence (IF) staining for histone H3. Surface expression of the integrin subunits a 1 , a 4 , a 5 , a L , a M , a X , b 1 and b 2 were measured by flow cytometry. Assessment of 2 0 ,7 0 -bis-(2-carboxyethyl)-5-(and-6)-carboxyfluorescein, acetoxymethyl ester (BCECF-AM)-labeled neutrophil adhesion to immobilized fibrinogen, fibronectin and intercellular adhesion molecule (ICAM)-1 was measured using a fluorescent plate reader. Neutrophil TEM across HUVEC monolayers was measured by flow cytometry. Hydrogen peroxide generation was measured using the Amplex UltraRed assay. Results: The requirement for integrin activation in NETosis was indicated by reduced NET release following EDTA treatment, Additionally, NETosis was induced by integrin activation with either Mn 2þ or macrophage-1 antigen (Mac-1, a M b 2 )-specific activation with leukadherin-1. Surface expression of a M and a X increased 3.1 and 2.5 fold respectively under hypoxia compared to normoxia controls (p < 0.001 and p ¼ 0.038 respectively). Previously, we found unstimulated and LPS-stimulated neutrophil adhesion to human umbilical cord vein endothelial cells (HUVEC) was increased under hypoxia (p < 0.01 and p < 0.001 respectively), so examined adhesion to immobilized ligands. Hypoxia significantly reduced adhesion to fibronectin (p < 0.01), fibrinogen (p < 0.01) and ICAM-1 (p < 0.01) compared to normoxia. In addition, neutrophil TEM was also enhanced by hypoxia compared to normoxia (p < 0.05). Interestingly, while we previously found a 1.6 fold increase in NETosis under hypoxia (p < 0.001), we did not find a significant effect upon ROS generation. Conclusion: We found that hypoxia significantly increased surface expression of a M and a X on neutrophils, adhesion to endothelial cells but not immobilsed integrin ligands, and TEM across HUVEC monolayers. Moreover, hypoxia did not affect neutrophil hydrogen peroxide production, but promoted NETosis. Further work is underway to determine the cell signaling and molecular mechanisms regulating these observations under hypoxia and whether purified IgG can further modulate these responses. Disclosure statement: The authors have declared no conflicts of interest.
HYPOXIA MODULATES NEUTROPHIL INTEGRIN EXPRESSION AND ACTIVATION
Background: While many rheumatoid arthritis (RA) patients respond to TNFa inhibitor therapy (TNFi), bloodstream neutrophils from RA patients express high levels of type-I interferon (IFN)-response genes, rather than TNFa-inducible genes. Curiously, patients with high expression of these IFN-inducible genes have the greatest response to anti-TNFa therapy. The aim of this study was to investigate the mechanisms leading to the expression of IFN-response genes by human neutrophils, and the potential roles of exogenous and endogenous TNFa expression. Methods: RNA-seq was performed on neutrophils from healthy volunteers following incubation with TNFa or the TLR8 agonist, R848, separately or together for 6h. Signalling pathway analysis was performed using Ingenuity Pathway Analysis (IPA). The expression of IFNs and IFN-response genes was determined by real-time PCR. IFN signalling was investigated by western blotting for phosphorylated STAT proteins.
Results: TNFa failed to induce expression of IFN-response genes, although it did induce the rapid (<1h) expression of many genes. IFNresponse genes were up-regulated by R848, but 5 h incubation with this TLR8 agonist was required for expression, suggesting secondary activation. IPA predicted activation of IFN signalling in R848-treated neutrophils. However, R848 did not induce type-I or type-II IFN transcripts, nor activate IFN signalling pathways via phosphorylation of STAT1 or STAT2. TNFa expression was induced by R848 and pretreatment of R848-stimulated neutrophils with infliximab (TNFi) significantly decreased expression of IFN-response genes. This implicates endogenous, but not exogenous, TNFa in induction of the IFN signature by R848. Conclusion: R848 induces chromatin remodelling in neutrophils, to allow transcription at normally silent promoters. These data suggest that this remodelling enables endogenous TNFa to (directly or indirectly) activate transcription of IFN-response genes. This indicates that in vivo, complex gene expression profiles of circulating neutrophils may result from multiple mechanisms of activation of gene expression that include chromatin remodelling. The implications of this phenomenon for understanding the molecular pathology of rheumatoid arthritis will be discussed. Disclosure statement: The authors have declared no conflicts of interest. Background: Anti-phospholipid syndrome (APS) is an autoimmune rheumatic disorder in which antiphospholipid antibodies (aPL) cause clinical events including vascular thrombosis (VT) and pregnancy morbidity (PM). The key antigen in APS is beta-2-glycoprotein I (b2GPI), which consists of five domains. The N-terminal domain (DI) carries the main immunodominant epitope. We previously showed that recombinant human DI blocks binding of serum IgG from patients with APS (APS-IgG) to whole b2GPI in ELISA and inhibits thrombosis induced by APS-IgG in a mouse model. We have since developed a method for the production and purification of a PEGylated form of DI which could potentially enhance its pharmacokinetic parameters opening up the possibility of using DI as a therapeutic. It has already been shown that the PEGylated form retains >80% of binding in an ELISA compared to the non-PEGylated form. It has also been shown that PEGylation can enhance the response of the protein in a clotting assay in comparison to the non-modified form of DI. This abstract represents the first time that PEGylated DI has been administered in an in vivo model of thrombosis. Methods: IgG was purified from the serum of a well-characterized primary APS patient (APS-IgG) or from normal healthy serum (NHSIgG) . A dose of 500 mg of APS-IgG or NHS-IgG was given i.p. to the mice at time 0 and 48 hours. Inhibitor (DI, PEGylated-DI or no-inhibitor control) was given 30-60 minutes after the IgG. At 72 hours, mice were anaesthetized and the femoral vein exposed. A total of 3 thrombi per mice were generated by standardized pinch stimuli and the crosssectional area of each thrombus measured. Tissue factor expression in peritoneal macrophages and carotids was also measured. Results: Thrombus size for the mice infused with APS-IgG was increased compared to mice given NHS-IgG (p < 0.001). When 40 mg of DI (a 2:1 molar ratio to antibody) was administered the thrombus induced by APS-IgG was reduced significantly (p < 0.001). Addition of either 40 mg or 20 mg of 20 kDa PEGylated DI showed significant inhibition (P < 0.05, P < 0.001 respectively) and both retained $75% of the activity of the non-PEGylated protein. Tissue factor was also down regulated in the groups given APS-IgG plus non-PEGylated DI or 40 mg PEGylated DI when compared to APS-IgG plus no inhibitor (P < 0.05). However, this outcome was not measured in the lower dose treatment group. Conclusion: PEGyated DI retains the ability to reduce thrombosis size in an APS mouse model of suggesting there may be significant therapeutic potential in the PEGylated molecules, provided that PEGylation extends in vivo half-life of DI. Background: Dysregulation of neutrophil activation is important to the pathogenesis of several autoimmune rheumatic diseases (ARDs), including rheumatoid arthritis (RA), systemic lupus erythematosus (SLE) and anti-phospholipid syndrome (APS). Neutrophils contribute the pathology of RA, SLE and APS via the aberrant production of reactive oxygen species (ROS) and neutrophil extracellular traps (NETs). Purified ARD-IgG has been shown to modulate NETosis, however the mechanism underlying increased NETosis is unknown. Integrin engagement and activation can regulate several aspects of neutrophil function, including cell adhesion, ROS production and NETosis. Therefore, we examined the effects of purified IgG upon neutrophil integrin activation and neutrophil activation to better understand how ARD-IgG modulates neutrophil function. Methods: Whole IgG fractions were purified from healthy control (HC), RA, SLE and APS serum using protein G columns. Peripheral blood neutrophils were isolated from HC or patients with RA, SLE or APS using Percoll gradient centrifugation. IgG binding to HC neutrophils was evaluated by flow cytometry. Neutrophil adhesion to immobilized fibronectin and fibrinogen was determined using a fluorescent adhesion assay. Hydrogen peroxide generation was measured using the Amplex UltraRed assay. NETosis was quantified using the QuantiT PicoGreen assay. Results: Significantly higher IgG binding was observed in neutrophils incubated with RA-, SLE-and APS-IgG compared to HC-IgG (p < 0.01). Further work found that binding of SLE-IgG was significantly reduced by FcgR blockade (p ¼ 0.0272), but not binding of HC-, RA-or APS-IgG. ARD-IgG also exhibited differential binding to integrins. APSIgG significantly enhanced adhesion to fibronectin (p < 0.05), which was significantly reduced with b 1 integrin blockade. In contrast, RAand SLE-IgG significantly increased neutrophil adhesion to fibrinogen (p < 0.05 and p < 0.001 respectively), which was inhibited by a M b 2 blockade. Ex vivo neutrophils isolated from RA and APS patients had similar rates of hydrogen peroxide production compared to HC. Neutrophils isolated from SLE patients however, had 1.4-1.7 fold lower rates of hydrogen peroxide generation compared to RA (p < 0.05), APS (p < 0.001) and HC (p < 0.05) derived neutrophils. Interestingly, RAand SLE-IgG increased ROS production in HC neutrophils by 1.5 and 1.6 fold compared to HC-IgG (p < 0.01 and p < 0.001 respectively). The presence of RA-and SLE-IgG also significantly enhanced spontaneous and LPS-induced NETosis compared to HC-IgG (p < 0.05 and p < 0.01 respectively). Moreover, RA-IgG also significantly increased PMA-induced NETosis compared to HC-IgG (p < 0.01). Conclusion: We found that ARD-IgG differentially regulates neutrophil activation in an integrin dependent manner. APS-IgG increased b 1 integrin-mediated binding to fibronectin, while RAand SLE-IgG promoted a M b 2 binding to fibrinogen, ROS production and NETosis. Given these differences in integrin activation and that SLE-IgG binding was reduced following FcgR blockade, our data suggest that RA-, SLE-and APS-IgG may be inducing neutrophil activation via distinct mechanisms. Further work is currently under way to dissect the signaling pathways underlying our observations. Disclosure statement: The authors have declared no conflicts of interest. Background: Neutrophils are central to the initiation, progression and resolution of inflammatory diseases such as rheumatoid arthritis (RA). We have previously shown that RA neutrophils have a gene expression signature indicating activation by type-I interferons (IFN), and that higher expression of IFN-response genes is associated with a good response to TNFi therapy. The aim of this work was to investigate the effects of type-I IFN on neutrophil function in vitro, alone and in combination with inflammatory cytokines. Methods: Neutrophils were isolated from healthy peripheral blood and incubated with Type-I IFN (IFNa) at a range of concentrations (up to 10ng/mL) in the absence or presence of GM-CSF (5ng/mL) and TNFa (10ng/mL). Apoptosis was measured at 18h by flow cytometry using annexin V/PI; ROS production was measured using luminol-enhanced chemiluminescence after stimulation with fMLP or PMA; protein expression/phosphorylation was measured by Western blotting; gene expression was measured by qPCR. Results: Neutrophils stimulated with IFNa in vitro underwent rapid phosphorylation of STAT proteins (5-30 min), activation of IFNresponse genes (1 h), and priming of ROS production (3 h). IFNa down-regulated the expression of chemokines (CXCR1, CXCR2, CXCR3, CCL3, CCL4) in response to both GM-CSF and TNFa (n ¼ 3, p < 0.05). IFNa alone did not delay neutrophil apoptosis, but addition of IFNa to neutrophil suspensions containing GM-CSF had a profound dose-dependent effect, where the protective effect of GM-CSF on neutrophil apoptosis at 18 h was significantly inhibited (n ¼ 3, p < 0.01). The abrogation of GM-CSF-delayed apoptosis was associated with significant loss of the anti-apoptotic protein MCL-1 by 6 h (n ¼ 3, p < 0.05). This loss of MCL-1 was not due to decreased transcription in response to IFNa (n ¼ 3, p > 0.05). Rapid turnover of MCL-1 protein can occur via caspase cleavage, or via proteasomal degradation following phosphorylation at multiple residues. IFNa activated the p38 MAPK pathway, implicated in cell survival and apoptosis. However, BIRB796, an inhibitor of p38 activity, did not block the IFNa-induced loss of MCL-1 (n ¼ 3, p > 0.05) or reverse IFNa-induced apoptosis in the presence of GM-CSF (n ¼ 3, p > 0.05). Conclusion: RA neutrophils have an IFN-induced gene expression signature. IFNa profoundly alters the functional effects of inflammatory cytokines on neutrophils in vitro. This may have important consequences in vivo during therapy with biologic drugs such as TNFi. The complexity and heterogeneity of inflammatory diseases such as RA, where different cytokines dominate or act synergistically to perpetuate systemic inflammation, may explain why some patients respond better to certain biologic therapies than others. Disclosure statement: The authors have declared no conflicts of interest. Background: Rheumatoid arthritis (RA) is a painful autoimmune disorder affecting more than 400,000 people in the UK with 12,000 new cases reported annually. Mechanisms underlying the development of RA are unknown, however it is hypothesized that presentation of auto-antigens to T helper cells promotes pro-inflammatory cytokine expression increasing the formation of Th1 and Th17 auto-reactive T helper cells. This in turn controls the inflammatory processes that characterize RA. Mesenchymal stem cells (MSCs) possess antiinflammatory and immunosuppressive properties which may modulate the immune response as therapy in refractory RA. This study compares MSC and MSC conditioned medium (CM-MSC) treatment in moderating T cell proliferation and proliferation of naïve T helper cells in antigen-induced arthritis (AIA).
PEGYLATED DOMAIN I OF BETA-2-GLYCOPROTEIN I PREVENTS THROMBOSIS IN A MOUSE MODEL

TYPE I INTERFERONS ALTER THE RESPONSE OF NEUTROPHILS TO INFLAMMATORY CYTOKINES
METABOLIC ANALYSIS OF RHEUMATOID ARTHRITIS NEUTROPHILS: A NEW WAY TO MEASURE ACTIVATION OF CELLS IN DISEASE
Susama
Methods: CD4 þ naïve T helper cells were isolated from splenocytes of healthy C57Bl/6 mice and seeded into a 96 well plate. Activated T cells were cultured alone or co-cultured with adhered MSC or with 50% CM-MSC in culture medium for 5 days. Proliferation was assessed through reduction in signal intensity using VPD450 Violet proliferation dye (BD Biosciences). T cell differentiation was investigated using spleens of C57Bl/6 AIA mice following treatment with MSC or concentrated CM-MSC or serum-free medium (SFM) as a control. Regulatory T cells (Treg) were isolated from spleens and assessed for CD4 þ CD25 þ FOXP3 þ expression. Whole splenocyte cell populations were restimulated with T cell Activation/Expansion beads (Miltenyi) for 4 hours and T cells assessed for intracellular cytokines indicative of Th1 (IFN-g), Th2 (IL-4) and Th17 (IL17a). Sections of joints from AIA mice were assessed using immunohistochemistry for macrophage numbers through detection of F4/80 (M1 and M2) and CD86 (M1) cells.
þ Treg showed significant increases in FOXP3 expression in MSC and CM-MSC compared to controls (p 0.01, p 0.05 respectively). There was a trend for increased Treg numbers in MSC and CM-MSC treated animals. Coculture with MSC significantly reduced number of proliferative cycles (p 0.005) and proportion of proliferating T cells (p 0.01). It was observed that co-culture with MSC also increased the lifespan of T cells without activation compared to controls. Intracellular cytokine expression showed significant increase in percentage of Th2 cells from mice treated with MSCs over both controls and CM-MSC treated animals (p 0.05) but also a significant increase in percentage Th17 cells over CM-MSC only (p 0.05). Treatment with CM-MSC had no significant effect on the M1/M2 balance of macrophages in the AIA joint. Conclusion: We demonstrate immunomodulatory properties of stem cells via altered activity of T cells. Restoring the T helper cell balance in RA could be a key therapeutic option in treating refractory RA. Further work will investigate the mechanism by which MSC influence T cell activation and proliferation to inform clinical translation. Disclosure statement: The authors have declared no conflicts of interest. Background: Treating the inflammation of rheumatoid arthritis (RA) early leads to improved patient outcomes. However, 30% will fail to respond to the first biologic drug tried and currently there is no way to predict which drug will be effective. This project aims to identify different RA immunophenotypes in order to predict treatment response to biologic drugs. Methods: RA patients with active disease (DAS28 >5.1) who were due to commence treatment with a biologic drug were included. PBMCs were stimulated with PMA and ionomycin or aCD3/aCD28 beads and analysed using 16-parameter flow cytometry for: a) T and B cell subsets; and b) Intracellular cytokine quantification (IFNg, TNFa, IL-13, IL-10, IL-17A, GM-CSF). Results: 7 RA patients and 9 healthy control (HC) samples were tested. There were large differences in the proportions of both IFNg þ T cells (range 8% to 65% in RA and 18% to 49% in controls) and IL-17A
T CELL SIGNATURES PREDICTING RESPONSE TO BIOLOGICS IN RHEUMATOID ARTHRITIS: TOWARDS DEVELOPMENT OF A 34 PARAMETER MASS CYTOMETRY PANEL
þ T cells (range 1.2% to 12%) within and between RA and HC. The proportion of IFNg þ T cells (Th1) did not correlate with that of IL-17A þ T cells (Th17), leading to the generation of 4 immunophenotypes: Th1, Th17, double-hi, and low, depending on cytokine expression. 3 month follow-up data were available for 6 RA patients. 5 had started an anti-TNF and 4 had a good EULAR response, with two of those having a double-hi phenotype. One anti-TNF non-responder had the Th17 phenotype. Conclusion: There is significant variability in cytokine expression of ex vivo stimulated PBMCs from RA and HC. Our next step is to investigate if this variability correlates with response to the first prescribed biologic drug with larger numbers per treatment group. These results have helped to develop a 34-channel mass cytometry (CyTOF) panel which has been optimized and is currently being further tested. Disclosure statement: The authors have declared no conflicts of interest.
INTERLEUKIN-23P19 IS UP-REGULATED IN MONOCYTE-DERIVED MACROPHAGES FROM HUMAN LEUCOCYTE ANTIGEN-B27-POSITIVE PATIENTS WITH ENTHESITIS-RELATED ARTHRITIS IN THE PRESENCE OF ENDOPLASMIC RETICULUM STRESS
Corinne Fisher, Anna Radziszewska, Debajit Sen and Yiannis Ioannou Arthritis Research UK Centre for Adolescent Rheumatology, University College London, London, UNITED KINGDOM Background: Enthesitis-related arthritis (ERA) is a HLA-B27-associated subtype of juvenile idiopathic arthritis most similar to the adult spondyloarthropathies (SpA). The innate immune system, intracellular stress response [the unfolded protein response (UPR)] and interleukin (IL)-23/IL-17 pathway are strongly implicated in the pathogenesis of adult SpA with both IL-23 and IL-17 now targets for treatment. However, the interplay between these biological processes and systems remains relatively poorly defined in SpA and unexplored in ERA. The objective of this study was to compare levels of the unique IL-23 subunit, IL-23p19, produced by monocyte-derived macrophages (MDMs) in the presence of lipopolysaccharide (LPS) and an inducer of the UPR [tunicamycin (TM)] from HLA-B27 positive and negative patients with ERA and healthy controls. Methods: Peripheral blood monocytes isolated from 18 patients with ERA (11 HLA-B27 positive, 7 HLA-B27 negative, median age 16 years 2 months, median disease duration 4 years 2 months) and 14 age and gender-matched healthy controls were differentiated in vitro with macrophage-colony stimulating factor (M-CSF). Cells were treated with interferon-g to up-regulate class I major histocompatibility complex-B and then stimulated with LPS alone or LPS with TM for 24 hours. IL-23p19 was measured by expression of messenger RNA using quantitative polymerase chain reaction (qPCR) and normalized against GAPDH. Results: IL-23p19 expression was higher in MDMs from HLA B27 positive patients with ERA compared to healthy controls treated with LPS and the UPR inducer, TM, ); p ¼ 0.0572], despite the small number of patients in the HLA-B27 negative group. Conversely, there was no significant difference in expression of IL-23p19 in MDMs stimulated with LPS alone, either between HLA-B27 positive and negative patients with ERA or from healthy controls. Conclusion: The increased expression of IL-23p19 in LPS-treated MDMs in the presence of TM in HLA-B27 positive patients with ERA suggests a potential role for IL-23 and the UPR in the pathogenesis of ERA, particularly in those who are HLA-B27 positive. Further studies in a larger number of patients are needed to confirm these findings and to determine whether there is a significant difference in IL-23 p19 production between HLA-B27 positive and negative patients. This may have important implications for treatment stratification in the future. 
Background:
The inappropriate recruitment and retention of T-cells into the joint is a cardinal feature of RA, yet the molecular mechanisms underpinning this remain unclear. We recently showed that patients with rheumatoid arthritis (RA) have a defect in a newly identified immunoprotective check-point (adiponectin-PEPITEM axis) that normally limits T-cell trafficking during inflammation. Here we examined the therapeutic potential of PEPTIEM in a murine model of arthritis. Methods: Collagen induced arthritis was trigger in DBA/1 mice by immunisation with bovine type II collagen. Synthetic PEPITEM was administered by daily injections starting at day 21 (prior to disease onset) or at the first signs of inflammation. Disease onset and severity were evaluated daily. Bone morphology and leucocyte infiltration were assessed by microCT, immunohistochemistry, flow cytometry and qPCR. Results: Administration of synthetic PEPITEM prior to disease onset inhibited the development of arthritis. We observed a significant reduction in disease incidence, clinical score, leucocyte infiltration and bone erosion when compared to control mice. Whilst we observed fewer leucocytes in the synovium, we detected higher levels of the FOXP3 transcript in PEPITEM treated mice than in control animals. Excitingly, PEPITEM also reduced the clinical score, leucocyte count in the synovium and damage to the bone when administered at the first signs of inflammation. Once again, we detected increased expression of FOXP3 mRNA in synovial tissue of PEPITEM treated animals. Conclusion: Thus targeting PEPITEM offers an alternative therapeutic approach for treating T-cell mediated diseases, such as RA. Background: Incomplete B-cell depletion following treatment with rituximab, a chimeric Type I anti-CD20 monoclonal antibody (mAb), is associated with poor clinical responses in patients with rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE), which can be augmented by delivering higher doses. Humanized type I anti-CD20 mAbs Ocrelizumab and/or Ofatumumab achieve comparable clinical responses to rituximab in RA and SLE suggesting that factors beyond human anti-chimeric antibodies such as defects in complement system, NK cells and macrophages may also contribute to inefficient B-cell depletion with rituximab, particularly in some patients with SLE. Further, internalisation may also impair the efficiency of rituximab-induced B-cell depletion. We hypothesized that mechanistically different Obinutuzumab, a Type II anti-CD20 mAb bearing afucosylated Fc portion may, at least partly, overcome disease-associated immune defects and outperform rituximab at inducing B-cell depletion in SLE. Methods: We used flow cytometry to perform: in vitro whole blood B-cell depletion assays to compare the efficiency of obinutuzumab and rituximab in depleting target B cells; surface fluorescence-quenching assays to determine the extent of mAb internalization; complement-dependent cellular cytotoxicity (CDC) assays to assess the ability to recruit complement and lyse target cells; NK-cell degranulation assays assessing surface expression of CD107a as a measure of antibody-dependent cell cytotoxicity (ADCC); and neutrophil activation assays assessing the surface expression of CD62L and CD11B. Obinituzumab-gly (obinituzumab with Fc-glycosylation similar to rituximab) was used to assess the effects of afucosylation. Direct cell death assays were also performed. Results: Obinutuzumab was greater than 2-fold more efficient than rituximab at inducing cytotoxicity in B cells from patients with RA and SLE in whole blood assays. Obinutuzumab was also internalized by isolated B cells from SLE patients to a significantly lower extent than rituximab with a median surface accessible mAb of 75% and 59%, respectively, after 6 hours of incubation. Obinutuzumab was significantly more efficient at inducing NK-cell activation, in RA and SLE; and also activated neutrophils more efficiently than rituximab in SLE. In contrast, rituximab was significantly more efficient than obinutuzumab at evoking CDC of isolated B cells. Obinutuzumab was also more efficient at inducing direct cell death in CD19 þ B-cells as a whole and switched (IgD-CD27 þ ) memory B-cells specifically, a higher frequency of which is associated with poor clinical response after rituximab. Conclusion: Our data indicated that Obinutuzumab is more efficient than rituximab at inducing B-cell cytotoxicity in vitro in both RA and SLE samples mediated by more effective FcgR-mediated effector mechanisms, including activation of NK cells and neutrophils and greater ability to remain at the cell surface following CD20 engagement and not be internalized. These data provide compelling mechanistic reasons for expecting better outcomes with obinutuzumab as an alternative B-cell depleting agent in RA and SLE, in particular. cytokines leads to the tissue damage in RA. The objective of this study was to investigate levels of circulating cytokines in the plasma and the profiles of cytokines secreted by mitogen-induced peripheral blood mononuclear cells (PBMC) in RA patients as compared to healthy controls and to study possible correlations with disease activity. Methods: 26 patients with RA (fulfilled 2010 ACR criteria) and 28 agematched healthy control subjects were inducted. RA patients were assessed using DAS 28 (Standard 28-Joint Disease Activity Score), CDAI (Clinical Disease Activity Index), SDAI (Simple Disease Activity Index), C-reactive protein (CRP) and Erythrocyte Sedimentation Rate (ESR). Pro-inflammatory cytokines (IFN-g, TNF-a, and anti-inflammatory cytokines (IL-4, IL-10, IL-13 and IL-23) were assayed in a multiplex ELISA system. Results: Patients with RA showed significantly higher plasma levels of TNF-a, IL-12 and IL-4 as compared to healthy controls (p ¼ 0.019, 0.042 and 0.013 respectively). Mitogen-activated PBMC cultures showed significantly higher levels of the pro-inflammatory cytokines TNF-a, IFN-g, IL-17 and IL-12 (p ¼ 0.044, 0.004, 0.002 and 0.046 respectively) but lower levels of the anti-inflammatory cytokine IL-10 (p ¼ 0.025) in RA as compared to normal healthy subjects. Ratios of TNF-a/IL-10, IFN-g/IL-10, IL-17/IL-10, IL-12/IL-10 and IFN-g/IL-13 were significantly higher in RA patients as compared to healthy controls (p ¼ 0.002, 0.0001, 0.0001, 0.001 and 0.014). The range and expression of cytokines was higher in mitogen-activated PBMC than in the plasma in all the groups studied. Significant correlation of plasma levels of IL-6 and IL-10 was observed with DAS-28, CDAI, SDAI and CRP. Multivariate pattern analysis of 9 cytokines revealed a prediction accuracy of up to 73% in differentiating patients RA from healthy controls. PBMC from RA patients with remission produced significantly higher levels of IL-6 as compared to patients with Active RA (p ¼ 0.027). However, there were no significant difference in levels of cytokines and cytokine ratios in PBMC and plasma. Multivariate pattern analysis of nine cytokines yielded a prediction accuracy of 69% in classifying patients as in remission or active RA. Conclusion: Compared to normal healthy women, RA patients had cytokine levels, ratios and production patterns that are markedly different in PBMC mitogen-stimulated cultures compared to the plasma suggesting that the estimation of the cytokine levels of PBMCs might be more reflective of the disease status compared to cytokine measurements in the plasma. Our data suggest that it would be worthwhile to explore ratios of pro-to anti-inflammatory cytokines produced by mitogen-stimulated PBMC in RA and the use of predictive algorithms for better prediction of this condition. 
CD8
þ T cells in synovial fluid (SF) of PsA patients compared to RA patients. We sought to determine whether IL-17-producing CD8 þ T cells may be found in joints of patients with UIA and whether these cells predict their eventual clinical phenotype. Methods: Paired peripheral blood (PB) and synovial fluid (SF) samples were collected from patients with UIA from Guy's Hospital Rheumatology Department with informed consent. Isolated PB mononuclear cells (PBMC) and SFMC were stimulated ex vivo using PMA/ ionomycin in the presence of golgistop before analysis of surface marker and cytokine expression by flow cytometry. Clinical measures of disease activity including C-reactive protein (CRP), erythrocyte sedimentation rate (ESR) and Disease Activity Score in 28 joints (DAS28) were recorded. Results: Ten patients with UIA with up to 12-month follow-up, were included in this pilot study. Four patients developed peripheral and/or axial spondyloarthropathy (SpA) satisfying the Assessment of þ Tcells identified a gene signature which could distinguish untreated early arthritis patients from disease controls. This signature was enriched for STAT-3 target genes whose expression correlated with circulating interleukin 6 (IL-6) levels. We hypothesize that pre-exposure of CD4þ T-cells to IL-6 mediates STAT-3 activation and subsequent aberrant effector function following T-cell receptor (TCR) stimulation, providing a mechanism of antigen non-specific immune dysfunction in early RA. Methods: Fresh blood was obtained from drug-naïve Newcastle Early Arthritis Clinic (NEAC) patients. Serum IL-6 was measured by MSD immunoassay. STAT-3 phosphorylation (pSTAT-3) and IL-6 receptors a and b (CD126 and gp130 respectively) expression of CD4 þ T-cell subsets was measured using flow cytometry. Naïve (CD45RA þ ) and memory (CD45RA
þ T-cells from healthy donors were cultured with IL-6 and equimolar concentrations of soluble IL-6R for 3 days, mimicking chronic exposure, before being washed and stimulated with anti-CD3/anti-CD28 for 6 days. Phenotype and proliferation were assessed by flow cytometry measuring cell surface markers and CFSE. RNA was extracted from cells at multiple experimental time points and global gene expression profiling undertaken by Illumina microarray. Results: Observational data from NEAC patients show naïve CD4 þ T-cells have higher constitutive pSTAT-3 compared to antigen experienced CD4 þ T-cells, which strongly correlate with serum IL-6 levels. Sensitivity to IL-6 appears to reflect gp130 expression which is highest in naïve CD4
þ T-cells with no difference in CD126 expression on CD4 þ T-cell subsets. In vitro pre-exposure of healthy control naïve CD4 þ T-cells to physiological levels of IL-6 caused significant STAT-3 gene induction which mirror genes previously found to distinguish RA patients from disease controls. These genes were less pronounced and unsustained in memory CD4
þ T-cells. Pre-exposure of naïve CD4
þ T-cells to IL-6 and subsequent TCR stimulation enhanced proliferative capacity and cell activation, in a dose-dependent manner. Interestingly, physiological levels of IL-6, mirroring those found in the serum of RA patient's strongly enhanced naïve CD4 þ T-cell proliferation. This effect was less pronounced in memory CD4
þ T-cells. In addition pre-exposure of CD4 þ T-cells to IL-6 resulted in altered cytokine profiles and T-helper cell differentiation.
Conclusion:
In the proinflammatory early RA disease state our data imply naïve CD4 þ T-cells have high constitutive pSTAT-3 activation which may be mediated by increased expression of gp130. Preexposure of cells to IL-6 caused increased proliferative capacity and activation status as well as differential gene expression, most prominently in the naïve CD4 þ T-cells. This highlights that cytokine 'pre-priming' during this critical phase may have consequences for naïve CD4 þ T-cell effector function impacting the transition to disease chronicity. Our findings may have implications for the optimal timing of biologic therapies in this disease. 
OKQ).
Methods: A steering group of people who are knowledgeable about osteomalacia, education and with experience of developing questionnaires was convened. It was decided to use true/false questions. Areas of knowledge of Osteomalacia were discussed according to their importance. Statements which were true or false were written. They were put into 8 sections of 5 questions each covering different areas of knowledge giving 40 in all. The questions were tested for utility and ambiguity in the group and modified and replaced accordingly. The questionnaire was then trialled in 37 people of South Asian origin in three groups. They were given the OKQ to complete and then had an education session about Osteomalacia, including a presentation and written or electronic material. They were retested with the OKQ after 6 weeks. There is no gold standard for measuring knowledge about Osteomalacia but increased knowledge should lead to an increase in vitamin D levels and decreasing parathormone levels. Vitamin D and Parathormone levels were measured alongside the OKQ in 2 of the groups before and after the education. Results: Baseline knowledge about Osteomalacia was low preeducation averaging only 12.7 out of 40 (range 0-29) (n ¼ 37). A total of 30 participants (81%) attended for the follow-up test. They averaged a score of 13.9 at baseline and 23.4 at follow-up. This was statistically significant (p ¼ 0.002 Mann Whitney) This shows that the OKQ is sensitive to change. Knowledge at baseline was correlated with vitamin D and PTH blood levels for two of the groups (n ¼ 27). This showed correlation coeficients of 0.128 and À0.407 respectively. For change of knowledge and change of parathormone (n ¼ 21) the r value was À0.324. While these are not statistically significant on these small numbers, they suggest a relationship between knowledge and PTH that is worthy of further study. Conclusion: A questionnaire has been developed that has face validity for testing knowledge about Osteomalacia. It has proved practical and shown sensitivity to change. It has shown promising correlation with biochemical measures of Osteomalacia. This questionnaire is worthy of further validation. Disclosure statement: The authors have declared no conflicts of interest. The objective of TPMP is to deliver contemporary, clinically applicable information directly to clinicians. By discussing formation of opinions and exploring clinical context, the podcasts allow listeners to access far more than pure data. This combination of evidence and implementation ensures seamless application to the clinical 'front line'. Contemporary journal articles, information on symptom recognition, how to proceed in different clinical scenarios and treatment options are discussed with Dr Gaffney. A portion of the podcast was also recorded with Matthew Briggs from the National Ankylosing Spondylitis Society, signposting clinicians and patients to invaluable information and support. Promotion and feedback is primarily via social media where the Podcast has a following of 13,146 across platforms (Twitter 7,621, Facebook 4,713, YouTube 812) and a dedicated email account. Results: To date there have been a total of 19,738 listens of over 90% of the audio (combined iTunes, Android and YouTube) and holds a 5 star rating on iTunes. Fifty percent of listeners are in the UK, Europe 18%, North America 14%, and rest of the world 18%. Health care professional split is Physiotherapists 80%, Chiropractors and Osteopaths 7%, Doctors 1% and others 13%. Feedback was received from a number of departments suggesting they were going to change practice and protocol as a direct result of the podcast. There was also feedback from a number of patients complimenting the information provided and voicing that there should be other similar projects raising awareness of SpA. Conclusion: Downloadable audio content counters many difficulties befalling the written material of both the formal (academic) and informal (blog) methods of Continued Professional Development. Mass dissemination across a number of platforms enables maximum reach and accessibility. The majority of listeners download or stream direct to an electronic device allowing for engagement while 'on the go' such as during commuting and leisure time. The success of 'Solving Spondyloarthropathy' Podcast, as well as subsequent podcasts, suggests that clinicians are increasingly interested to receive their CPD material in audio format. The level of interest and feedback received from this Rheumatology podcast suggests that similar projects would be well received. This represents a novel, efficient and rapid way of disseminating the latest information, research and best practice. Disclosure statement: K.G.: Member of speakers bureau: Abbvie, USB, Pfizer, MSD. Grants/research support; Abbvie, Pfizer. J.M. has declared no conflicts of interest.
THE PHYSIO MATTERS PODCAST: SOLVING SPONDYLOARTHROPATHY
THE VIEWS AND PERCEPTIONS OF NON-SPECIALIST, HOSPITAL JUNIOR DOCTORS ON JOINT ASPIRATION OF THE ACUTE HOT SWOLLEN JOINT AND THEIR TRAINING IN THIS CLINICAL SKILL
Ziad Farah
Rheumatology, Northwick Park Hospital, London, UNITED KINGDOM Background: BSR guidance on managing hot swollen joints recommends early joint aspiration (arthrocentesis) to rule out septic arthritis and avoid morbidity and mortality. In such patients, the initial assessment is often performed by junior doctors prior to specialist review. Previous audit suggests poor adherence to recommended guidance. Our previous quantitative survey in 2 hospitals found low self-reported confidence at managing hot swollen joints in 72 of 140(52%) respondents; 58(42%) participants reported inadequate exposure, and 43(31%) inadequate training. There is limited research, however, exploring the reasons behind poor uptake of arthrocentesis by junior doctors. Methods: The focus group included two foundation doctors, two senior house-officers and two registrars. Focus group questions were developed from themes that emerged from our previous quantitative survey. The session was recorded using an iPhone, then anonymously transcribed verbatim. The transcript was analysed using an emergent coding technique drawn from grounded theory approach. The data were coded over three passes. Results: The decision to aspirate a joint appeared to be influenced by internal and external factors. Internal factors included their previous experience, which was variable with one who did 7 aspirations and another who [had] not had any experience at all. Other factors like anatomical knowledge, level of seniority and prior training were presented. Negative emotions emerged with participants using words like weary, anxious and scary, particularly fear of serious consequences when describing joint aspiration. External factors included procedure-related factors like technical difficulty, and the type of joint to be aspirated. Consensus suggested that all joints except the knee should be left to the specialist. Context-related factors included time constraints. The group emphasized the importance of recurrent exposure and opportunity to practice aspirations. Availability of supervision influenced the decision to aspirate, particularly if by the rheumatologist. Training in arthrocentesis appeared to be inconsistent. Positive comments included succinct dedicated training experiences by an expert using simulation, immediate feedback followed by practice. Negative comments emerged such as training was inconsistent and of poor timing, or trainees lacked the opportunity to subsequently practice. Participants then proposed methods of how to improve training in arthrocentesis. Conclusion: The decision to aspirate is a complex interaction between internal and external factors combining knowledge, attitudes and emotions with circumstances and context. The participants emphazise training in knee aspirations, but not other joints due to lack of exposure. Immediate feedback during training in arthrocentesis is key. Inability to continue regularly practicing the procedure in real patients may be a barrier to retaining the skill. A review of training in joint aspiration may be required in order to improve uptake of this skill in practice. Background: A sound knowledge and confidence in musculoskeletal (MSK) anatomy is correlated with the clinical assessment and diagnosis in rheumatology. The bedside clinical skills of the rheumatologist have historically been widely respected and called upon when one is faced with the most complex diagnostic challenges. More recently, the specialty has offered career progression with opportunities to develop practical skills such as joint injection and MSK ultrasound, both of which require a sound understanding of clinical anatomy. In the UK, MSK anatomy is a relatively neglected component of postgraduate rheumatology training. There is currently a lack of uniformity in the way that anatomy is taught and applied which differs from surgical specialties, and can only add to the confusion and frustration of trainees. There is growing evidence that the knowledge of MSK anatomy and the performance of a competent MSK examination are deficient at multiple levels of medical education, including rheumatologists and their trainees. The Joint Royal Colleges of Physicians Training Board (JRCPTB) in the UK outlines the need for postgraduate training in anatomy in the specialty curriculum, although currently there are no formal strategies to support a competencybased learning approach. This study aimed to evaluate an applied anatomy course, involving cadaveric material, targeted at specialists in rheumatology. Background: In the UK, musculoskeletal disorders are one of two major causes of incapacity for work and cost an estimated 0.5-2% of gross domestic product. A recent survey of 200 rheumatology patients by one UK centre, suggested that patients were not seeking workrelated advice from their GP or hospital consultant prior to stopping work. The aim of this survey was to look at Rheumatologists' knowledge and attitudes towards occupational rheumatology and to see if there was a need or interest for further training. Methods: Rheumatologists in two regions of the UK were asked to complete a paper survey. It consisted of 13 questions relating to knowledge and attitudes towards occupational rheumatology. All answers were anonymized and confidential. Results: The survey was completed by 56 Rheumatologists including 38 consultants (68%), 4 associate specialists (7%) and 14 SpRs (25%). There was no significant difference between the results for the two regions. 95% of doctors felt that they were regularly being asked about work-related issues by their patients. Only 13% (7 consultants) have had any previous training in this area of medicine. Doctors did not feel confident to give advice about work and benefits with a mean Likert rating of 1.1 for registrars and 1.9 for senior doctors (1 ¼ not confident to 5 ¼ very confident). Doctors perceived barriers to discussing this topic with patients were time and knowledge. Individual comments included I don't think it's my role and I think we have enough to talk about. 86% (49/56) doctors would like further training in occupational rheumatology, however no clear learning preference was identified between a lecture, information leaflet or online. Conclusion: These data suggest that occupational rheumatology is an important area of medicine, which is not being addressed in current training. Doctors lack confidence to answer questions about work-related issues. Common barriers identified are doctor knowledge and a lack of clinic time. We believe that this is the first survey to evaluate doctors' knowledge and attitudes towards this area of medicine. Currently, there are no curriculum requirements related to occupational issues in the specialist curriculum. Nearly all doctors would like further training in this area of medicine. Hopefully this will positively impact on work place retention and patients' ability to work. Disclosure statement: The authors have declared no conflicts of interest.
Background: For many rheumatology patients MOVE is viewed as a four-letter word, despite compelling evidence about the importance of exercise and the risks associated with a sedentary lifestyle. We decided to use rheumatology appointment waiting times as an opportunity for patients to learn about exercise through direct experience. We developed two programmes: Exercise-while-youwait walkway and a 2-minute stretch sitting exercise programme, and assessed patient response. Methods: We designed both programmes to include ten simple exercises to engage all major muscle groups, joints and spine. Both programmes can be done independently or with the assistance of trained volunteers before or after appointments, and have clear accompanying leaflets. The 2-minute stretch also has a YouTube video version. The Exercise-while-you-wait walkway starts and finishes with a one leg balance test with eyes closed ('stork test') as a measure of balance, and hence falls risk. The walkway exercises are illustrated with photographic collages and simple instructions. After validating safety and feasibility, we invited patients to complete the walkway and measured the stork test and well-being (100mm VAS) before and after completing the walkway. We also looked at patient enjoyment, barriers to the walkway and whether they felt they would continue the exercises at home. The 2-minute stretch sitting exercise programme was designed to raise energy expenditure above sedentary to help to reach a wider population including chair-bound, sedentary lifestyle and those with low self-confidence for physical activity. We asked patients how they felt after doing the exercises and if they would do them at home. Results: Main study (n ¼ 108) showed mean stork test time improved 13.2 to 18.4 seconds (p < 0.001); importantly, patients with lowest stork time (<4 seconds) reduced from 25 (24%) to 10 (9.4%) (p < 0.001). In a separate cohort (n ¼ 94), general well-being VAS score improved from 52.1 to 59.3 (p < 0.001) after the walkway. 94% patients preferred the walkway to sitting in the waiting room and reported they would continue the exercises at home. 85% of patients had a BMI >30; a negative correlation was observed between BMI and walkway enjoyment. The main barriers to using the walkway were selfconsciousness, idleness, and worries about missing appointments. 59% of patients said they would not exercise alone and 92% preferred supervision. 95% (n ¼ 75) rheumatology patients felt better after doing these exercises; 82% (n ¼ 65) said they would continue at home. Conclusion: Hospital appointments provide opportunities to break down barriers which prevent them from exercising. We present two simple exercise programmes that allow patients to learn about exercise through experience. These programmes are safe, efficient and cost-effective methods of promoting exercise. They are transferable to primary and secondary care and can be developed to suit individual patients' needs. North Bristol Academy, North Bristol NHS Trust, Bristol, UNITED KINGDOM Background: Simulation teaching is an emerging field in medical education, however it has not been used commonly in the field of rheumatology in the past. We decided to evaluate whether this technique could be used successfully among third year medical students from Bristol University during rheumatology teaching as part of the Musculoskeletal Diseases, Emergency Medicine and Ophthalmology (MDEMO) placement. Methods: 2 clinical scenarios were devised: The first: Simulation of the acute hot joint -an actor was given a history consistent with septic arthritis and a heat pack and make-up were applied to the knee to simulate the warmth and redness of inflammatory synovitis. Secondly, Simulation of giant cell arteritis (GCA) -a patient with known GCA was brought in and asked to act as if his presenting symptoms had just started. Students worked through both scenarios in pairs and were expected to take a focussed history and to examine the patients picking up on the simulated signs where present. The students were asked to present their differential diagnosis to a senior nurse (plant) before arranging initial investigations (with subsequent interpretation of preliminary results) then deciding upon and charting initial management. Detailed feedback was provided by the assessor to consolidate the learning points. Students were asked to complete a feedback form at the end of each scenario. Results: 13 students provided feedback on each of the simulated cases. Combined analysis of the feedback from the 2 scenarios showed that students scored the scenarios highly for usefulness (91.5%), relevance (96.2%) and realism (85.4%). They also felt that the scenarios were pitched at the right level (88.5%) and they appreciated the detailed feedback and teaching received during the debrief session (95.8%) at the end of the scenario. The overall combined score for the two sessions was 94% and 25 of the 26 respondents (96.2%) felt more confident on the subjects (with one respondent unsure following the acute hot joint scenario).
Conclusion: This pilot study shows that simulation teaching can be used successfully in the teaching of rheumatology to medical undergraduates. The technique provided an effective means of simulating real world scenarios relating to 2 important conditions that may not be experienced in the course of a short undergraduate placement and that can be catastrophic if poorly managed. Students reported that these additional sessions complemented and consolidated what they had learnt during the rest of their placement and they felt more confident in the assessment and management of these conditions. Background: Methotrexate (MTX) is the first-line disease modifying anti-rheumatic drug (DMARD) for the treatment of rheumatoid arthritis (RA). By two years of treatment only 55% of patients remain on the drug, implying that many do not respond adequately or experience adverse effects. Therefore, identifying blood-based biomarkers that predict treatment response is an important research priority. DNA methylation is an epigenetic marker that modifies but does not alter DNA sequence, and should be considered for evaluation as potential biomarkers for treatment response. The mechanisms of action of MTX are unclear. However, it is thought that MTX promotes adenosine release and interferes with the intracellular methyl donor status leading to DNA hypomethylation. Here, we aimed to identify differential DNA methylation signatures in whole blood, which may act as biomarkers predictive of response to MTX in patients with RA.
Methods:
DNA methylation was measured using the HumanMethylation450 BeadChip in whole blood-derived DNA samples from individuals recruited to the Rheumatoid Arthritis Medication Study (RAMS), a one year observational study including patients with RA starting MTX for the first time. DNA was extracted from blood samples collected pre-treatment (baseline) and following four weeks on therapy from patients who subsequently (at 6 months) were determined to have had a EULAR good response (n ¼ 36) or EULAR poor response (n ¼ 36) to MTX, according to their disease activity score [DAS28-C-recative protein (DAS28-CRP)]. Differentially methylated positions (DMPs) between the baseline and four weeks, and between good and poor response were identified using linear regression, adjusting for gender, age, cell composition, and baseline DAS28 score. Analyses also compared methylation levels with changes in DAS28 and the individual DAS28 components over six months. Results: Based on percentage change in methylation, and p-value (<10 À5 ), there were two DMPs identified at 4 weeks, which associated with response. An additional three DMPs were associated with change in tender joint count, whilst three other DMPs were associated with change in swollen joint count, and a further four DMPs associated with change in CRP. Conclusion: These preliminary results suggest DNA methylation may provide a useful source of biomarkers of MTX response. Further analysis is being conducted and significant findings are being validated in the total RAMS population using pyrosequencing. Background: 17 genetic loci have now been identified to confer susceptibility to juvenile idiopathic arthritis (JIA); several of these loci harbour genes involved in the Interleukin-2 (IL2) pathway suggesting that this may be an important signalling cascade involved in JIA. It is hypothesized that these regions may act as regulatory elements that modulate gene expression. Indeed capture Hi-C data, which identifies physical DNA interactions, have shown that interactions occur between a JIA susceptibility SNP rs9979383 located in a non-coding region, and the Runt-Related Transcription Factor (RUNX1) gene a crucial transcription factor involved in the regulation of IL-2. Here we use bioinformatics analysis to prioritize the likely functional variant at this locus and Chromatin Conformation Capture (3C) to validate suggested genotype specific interactions.The aim of this study is to design a bioinformatics pipeline to prioritize the most likely functional candidate SNPs and to design and perform functional experiments to define the mechanisms by which these JIA associated variants contribute to disease pathogenesis. Methods: To prioritize the most likely functional candidate SNPs in the RUNX1 region several bioinformatics databases were curated along with In-house generated Capture Hi-C data to assess interactions between associated SNPs and nearby IL2 pathway genes. Fragments near JIA associated SNPs showed looping at several points around the haematopoiesis master regulator gene; RUNX1. Chromosome Conformation Capture (3C) experiments were performed to validate interactions in the selected regions. To test for genotype specific effects nine B-lymphocyte cell lines, three of each genotype, were selected for this experiment. Results: The highest prioritized SNP in the RUNX1 gene region was identified as rs9799383 based on transcription factors, Hi-C data and histone marks. Analysis of 3C data show some interactions occurred significantly more frequently in four fragments compared to the negative control. The interacting fragments were located near the RUNX1 short isoform promoter region, with the most significant interactions occurring in the CC genotype cell lines. One interaction in particular shows evidence of a 400kb looping interaction between the JIA associated SNP fragment and a fragment containing evidence of PU.1 binding.
Conclusion:
The bioinformatics approach proved to be highly informative and aided the design of 3C experiments. The ability to analyse the data, both overall and by genotype has revealed the presence of long range interactions and indicates that increased looping is primarily driven by the protective allele. Further experiments have been designed to examine whether a similar genotype specific effect can be observed in PU.1 binding in this fragment and could be indicative of a distal regulatory effect that may influence gene expression of RUNX1.
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Thursday 27 April 2017 ii153 þ T cells of untreated early arthritis patients. Here, differences in eQTL effects between patients according to diagnosis or autoantibody serotype were sought in an effort to shed light on genetic risk mechanisms. Methods: Allelic expression imbalance (AEI) was employed as a sensitive tool for validating and comparing cis-eQTL effects. In total, residual cell-specific DNA and RNA were available from 54 patients with varying diagnoses (ACPA þ RA, ACPA À RA, Non-RA Inflammatory arthritis, Non-inflammatory arthralgia), who were heterozygous for at least one of the eQTL SNPs of interest (rs10876864, rs2210913, rs4795397, and rs9916765). In each of the heterozygous patients, relative expression of the associated gene copies was quantified by pyrosequencing at transcript SNPs in high linkage disequilibrium (r 2 ! 0.9) with the eQTL SNP. Detailed clinical information was available for participants, all of whom gave written informed consent. Assigned diagnoses were confirmed at ! 1 year follow-up. Results: We were able to validate the presence of cis-eQTLs regulating the expression of FCRL3, GSDMB, and IKZF3 with mean AEI (risk:protective) of 1.75, 0.82, and 1.17 respectively (p < 0.0001 in each case). However, no such imbalance was observed for RPS26 (p ¼ 0.094); this contradicted the genomic data, and the original observation was likely due to a cross-hybridizing array probe. Differences in AEI at IKZF3 and FCRL3 as a result of disease phenotype were detected. Specifically, AEI at IKZF3 was of increased magnitude among RA patients compared with non-inflammatory arthralgia patients (1.19 vs. 1.12, p ¼ 0.009). Among RA patients, AEI at FCRL3 was significantly reduced in anti-citrullinated peptide autoantibody (ACPA) seropositive individuals compared with both their seronegative counterparts (1.45 vs. 2.15, p ¼ 0.029) and patients with non-inflammatory arthralgia (1.45 vs. 1.92, p ¼ 0.018). In the case of FCRL3, overall levels of gene expression were increased in seropositive patients.
Conclusion: Here we demonstrate the utility of AEI as a means of validating cis-eQTLs, the importance of which is highlighted by the absence of imbalance at the RPS26 gene. AEI affords greater sensitivity over multivariate analysis for detecting the impact of clinical covariates or disease phenotype on eQTL activity, as demonstrated for the FCRL3 gene in seropositive RA. Whether or not disease subsetspecific epigenetic variation underpins this observation is the subject of ongoing study. AEI therefore represents an important means of prioritizing potentially pathogenetic genes for mechanistic evaluation and functional characterisation. Background: Hand osteoarthritis (OA) diagnosis is based on a combination of clinical, imaging features and assessment of risk factors, together with clinical associations and outcomes. Without established Heberden and Bouchard nodes and/or bony enlargement and characteristic involvement of proximal and distal interphalangeal joints (PIPs and DIPs), thumb base and index and middle metacarpophalangeal joints (MCPs), the early diagnosis of hand OA is more difficult. Our study aimed to investigate the usefulness of a standardized US examination protocol for hand joints in diagnosing OA in patients who did not fulfil the clinical criteria for OA. In addition, we correlated the US findings with clinical, inflammatory and radiographic parameters, to determine which type of investigations are the most useful for diagnosing hand OA. Methods: A retrospective, observational study was conducted including 62 patients with hand OA. Information about age, disease duration, ESR, CRP, ultrasound (US), radiographic and clinical joint examination (CJE) were captured for every patient. On US, synovial hypertrophy (SH), Power Doppler (PD) signal, number of osteophytes (OPs) and erosions were assessed. On CJE, tender joint count (TJC), swollen joint count (SJC) and pain scores (VAS) were obtained. We compared the 30 joint score of the hand, (including MCPs, PIPs, DIPs and CMC1 joints) with smaller, pre-defined joint scores including two scores of 22 and 12 joints each and another 10 and 6 joint scores for OA. We correlated the US findings with radiographic scores. Results: As shown in Table 1 , X-ray osteophyte scores correlated very well with all the US scores detailed above (R ¼ 0.381À0.645, P < 0.05), despite having a low sensitivity for detection of osteophytes (58.6%), and an even lower sensitivity for detection of erosions (38.4%), when compared with the 30 joint US score. There was a good correlation between different US scores, apart from the 6 joint score assessing only DIP 2-3 and CMC 1 bilaterally, which missed information by not assessing the PIP joints (R¼ À0181À0.207, P > 0.05). Conclusion: US examination of the hands can facilitate diagnosis of hand OA in patients who do not fulfil the ACR criteria, by identifying the presence of osteophytes with the particular distribution and number required for diagnosis in a proportion that was three times higher than that of patients diagnosed based on clinical examination and hand Xrays alone. The US examination of only 10 joints (PIP 2À3, DIP 2À3 and CMC 1 bilaterally) was as informative as the extensive joint examination protocol including 30 hand joints for diagnosing hand OA. 262 Other common diagnoses included polymyalgia rheumatica (13.9%) and seronegative peripheral inflammatory arthritis (9.9%). Infection (5.4%) and malignancy (3.5%) were uncommon. Conclusion: Suspected large vessel vasculitis is the most common reason rheumatologists request PET-CT scans. LVV should be considered in patients with GCA or PMR who have poor response to treatment or unexplained raised inflammatory markers. CRP level prior to PET-CT scan does not differentiate inflammatory disease, malignancy or infection, but does correlate with extent of disease in patients with LVV. Infection and malignancy are uncommon in inflammation of unknown origin, but PET-CT scan is this context can identify both infection and malignancy at unusual or occult sites. Disclosure statement: The author has declared no conflicts of interest. Background: Patients with genetic haemochromatosis (GH) develop an arthropathy (HA) resembling primary OA. HA may be distinguished from primary OA by high prevalence of MCP and ankle joint disease, as primary OA at these sites is unusual. As the time from first joint symptoms to diagnosis of GH is often delayed 5 years or more, we have investigated MRI features of the hindfoot that might distinguish GH cases from primary OA. Methods: We conducted a retrospective case-control study comparing 30 MRI studies of GH patients with hindfoot arthropathy with 30 gender and age matched controls with primary hindfoot OA. GH cases were identified from a specialist clinic and controls from a search of the St George's PACS. Images were anonymized and scored by two MSK radiologists using a semiquantative tool adapted from the MRI osteoarthritis knee score (MOAKS). Scores were generated for bone marrow lesions (BML)/cysts for size, number and % that were BML as distinct from cysts (0 -3). Articular cartilage was scored for presence and extent (0-3) of full thickness loss and osteophytes by size (0-3). The primary outcome was BML/cyst size. Paired Student's t-test and Chi squared were used to compare outcome measures between GH and paired controls. Results: The BML/cyst % score indicated that in both GH and OA controls these lesions were predominantly cysts. The score for BML/ cyst size was significantly higher in the ankle joint for GH cases compared to paired controls (p ¼ 0.001) but not in the middle or posterior subtalar joints. In the ankle joint, GH scores were significantly higher than paired controls for 5 of 7 secondary outcomes (see Table 1 ) (p < 0.05), in the middle subtalar joint for 3 secondary outcomes (p < 0.05) and for no measures in the posterior subtalar joint. Conclusion: The finding of both numerous and large cysts on MR imaging of the ankle should raise the suspicion of GH, prompting measurement of ferritin and transferrin saturation. Other MRI features of potential diagnostic value for GH include large osteophytes and the presence of extensive full thickness cartilage loss in the ankle and middle subtalar joints. 264 Disclosure statement: The authors have declared no conflicts of interest.
MAGNETIC RESONANCE IMAGING HINDFOOT CHARACTERISTICS OF GENETIC HAEMOCHROMATOSIS: A CASE-CONTROL STUDY
EFFICACY OF ULTRASOUND-GUIDED VERSUS LANDMARK-GUIDED INJECTIONS IN RHEUMATOLOGY: A SYSTEMATIC REVIEW
Christos Koutsianas and Rainer Klocke Department of Rheumatology, Dudley Group NHS Foundation Trust, Dudley, UNITED KINGDOM Background: There is good evidence that ultrasound (US) increases the accuracy of needle placement for aspiration and injection of joints. However, considerable uncertainty remains as to whether US-guided injections (USGI) achieve better clinical outcome in rheumatic conditions compared with landmark-guided injections (LGI), and how any effect on outcome relates to accuracy. Methods: We conducted a literature search using PubMed for the period up to 9 September 2016, yielding 810 references. After applying RCTs, human studies and relevance to rheumatic conditions as eligibility criteria, abstract review produced 25 studies, all using corticosteroids as injectate. Study design quality was assessed using the Jadad scale.
Results: The median sample size of the 25 studies was 60 (range 20-244) patients. 11 studies evaluated shoulder injections, 3 targeted multiple joints, while knee, wrist, plantar fascia and carpal tunnel were investigated in 2 trials each. Single trials investigated injections of Morton's neuroma (MN), flexor tendon sheaths (FTS) and scapulothoracic bursa (STB). Median Jadad score was low at 2 (1-5). Only 5 RCTs had an effective double blinding method, with sham-US/blindfolding of patients and a blinded outcome assessor. 16 of 25 (64%) trials showed superior outcome of USGI compared to LGI for one or more outcomes measuring pain, function or range of movement. The three RCTs with the lowest risk for bias (subacromial, MN, multiple joints) failed to demonstrate clear USGI superiority for the main clinical outcomes. In the 4 studies that assessed both accuracy and efficacy, USGI did not show superior outcome but superior accuracy in 2/4 (multiple targets and wrist) studies. In those two studies accurate injections were associated with better outcome of at least one main clinical criterion.
Conclusion: The quality of available evidence comparing USGI to LGI on clinical outcome for rheumatologic conditions remains limited. The majority of trials suggest US guidance associates with superior outcome of injections. However, higher quality RCTs and trials with similar accuracy between the two techniques fail to support this. There is need for further trials with better design and adequate sample power. Background: Musculoskeletal (MSK) ultrasound (US) scanning is established as a useful clinical tool in decision making and improving clinical outcome in patients with inflammatory arthritis.The aim of this study was to review the impact of the introduction of a dedicated early inflammatory arthritis (EIA) ultrasound clinic to an existing general MSK US clinic and to review any change in referral patterns. Methods: All patients who were referred to the rheumatology musculoskeletal ultrasound service were analysed within a three month time period. 147 referrals were made between 3 June 2016 to 2 September 2016. Three Consultant Rheumatologists carried out and reported the ultrasound scans. Scans were carried out using a GE Logiq E machine. Synovitis was defined as grey scale synovial hypertrophy or tenosynovitis, with or without hyperaemia. Data were collected from both paper and electronic patient records. Results: 6 patient records were missing, hence a total of 141 US scan referrals were included in our analysis. Of these 141 referrals, 5 did not attends (DNAs). 122 (86.5%) of referrals were for early inflammatory arthritis (compared to 71% the year before). The two most frequently requested US scan were as follows: hands and wrists (52.5%), hands and wrists and feet (21.3%), similar to the previous year. The majority of referrals were US scan alone (94.3%). Out of 141 scans, 43 patients (30.5%) had synovitis, 84 (59.6%) had no synovitis, 9 patients (6.38%) had no diagnosis, 5 patients (3.55%) were DNAs. The US scan reports influenced the clinical decisions as following: for 20 patients (14.2%) a disease modifying anti-rheumatic drug (DMARD) was started, for 6 patients (4.26%) a biological therapy was started, for 2 patients (1.42%) the current DMARD was continued, for 2 patients (1.42%) physiotherapy was recommended, for 2 patients (1.42%) hand therapy was recommended, for 2 patients (1.42%) further imaging was recommended, for 1 patient (0.709%) podiatry referral was recommended, for 1 patient (0.709%) the DMARD was stopped. A therapeutic intervention occurred as a result of the MSK US in 84.8% of cases similar to the previous year. The discharge rate from the Rheumatology service as a result of the scan was 4.97% compared to 24% the previous year. 3 joint injections were carried out. Conclusion: A higher percentage of patients scanned had been referred for EIA, possibly as there were dedicated EIA slots. Introducing a second dedicated EIA scanning clinic builds in resilience to a rheumatology based MSK US service without diluting the impact on therapeutic intervention. Disclosure statement: The authors have declared no conflicts of interest.
FIRST DEMONSTRATION OF A CHANGING IMAGING PHENOTYPE DURING FLARES OF PALINDROMIC RHEUMATISM
Kulveer Mankia, Maria Antonietta D'Agostino, Richard Wakefield, Laura Horton, Jackie Nam, Andrew Grainger and Paul Emery Academic Rheumatology, Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, UNITED KINGDOM Background: Palindromic rheumatism (PR) is a recurrent, selfabortive arthritis and/or para-arthritis which progresses to RA in up to 50% of patients. The anatomical basis of palindromic flare remains uncharacterized. We aimed to describe changes in US and MRI phenotype during and between PR flares. Methods: Patients were recruited from a prospective PR cohort. Palindromic flares were defined as ! 2 of pain, swelling, erythema in/ around ! 1 joint, that later normalised. Blinded US assessment (wrists, MCPs, PIPs, elbows, knees, MTPs, ECUs and 2nd-5th finger flexor tendons) was performed during and between flares. Synovitis, tenosynovitis, subcutaneous oedema, peri-articular inflammation and peri-tendinous oedema were reported at each joint. MRI was performed at baseline and on the most symptomatic region during flare and scored descriptively for the above pathology. Results: US was performed in 22 patients during flare. 19 patients also had a non-flare US. Mean age was 49 yrs. 16/22 (73%) were anti-CCPþ and 6/22 (27%) were anti-CCPÀ. All but 2 were DMARD-naïve.
On flare US, grey scale synovitis was present in 13/22 (59%) patients and Power Doppler (PD) synovitis was present in 4/22 (18%) patients. No erosions were found. 12/22 (55%) patients had peri-articular inflammation and/or subcutaneous oedema. In 6 patients this was without synovitis/tenosynovitis. Tenosynovitis and/or peri-tendinous oedema were present in 6/22 (27%) patients. US abnormalities were less prevalent on non-flare US (Table 1 ) including improvement in 6/7 patients in whom non-flare US followed flare. In 5 patients who had > 1 flare, the prevalence of intra-and peri-articular US abnormalities varied in sequential flares. MRI was performed on 9 patients; synovitis and tenosynovitis were more prevalent in flare vs baseline scans (80% vs 50% patients and 60% vs 33% patients respectively). Subcutaneous oedema was seen only in flare (40% of patients). Bone marrow oedema (BME) was found in 1 patient. No erosions were seen. Conclusion: The PR imaging phenotype changes in flare and is characterized by peri-articular inflammation and subcutaneous oedema, often without synovitis. Low prevalence of PD synovitis, BME and erosions further distinguishes PR from RA. The prognostic value of imaging phenotype will be determined on follow-up.
267 TABLE 1. Comparison of US abnormalities in 19 patients scanned during both flare and non-flare periods.
US abnormality
Non
Disclosure statement: The authors have declared no conflicts of interest.
IMPACT OF MUSCULOSKELETAL ULTRASOUND TO EVALUATE SUSPECTED INFLAMMATORY ARTHRITIS IN THE CITY HOSPITAL RHEUMATOLOGY DEPARTMENT: A SERVICE EVALUATION
Tochi Adizie, Amy Livesey and David Carruthers Rheumatology, City Hospital, Birmingham, UNITED KINGDOM Background: Over the last 2 decades, musculoskeletal ultrasound (MSUS) has become a widely used diagnostic tool in rheumatologic practice because it is easily accessible, cost-effective, non-invasive, and well tolerated by patients. Increasing amounts of literature have confirmed that MSUS is superior to clinical examination in detecting synovitis. It is particularly useful in the evaluation of patients with suspected early inflammatory arthritis. The identification of these patients may allow clinicians to initiate early aggressive therapies in order to minimize joint destruction and functional loss. However, definitive guidelines on the use of this technology in clinical practice have yet to be devised. Methods: We carried out a service evaluation of all patients in our department who had undergone Ultrasound Hands, Wrists and/or Feet in the 12 month period from May 2015 to May 2016. We collected demographic data as well as information on indication, serology, inflammatory markers, correlation between ultrasound findings and clinical examination and whether the ultrasound result influenced the resulting management of the patient. Patients were categorized into two groups those with and those without synovitis detected by ultrasound. Their characteristics were compared using chi-square and Students' tests, to try and determine which variables were significantly correlated with presence of synovitis. Results: We identified 148 patients. 43% (63/148) had an established diagnosis of an inflammatory arthritis. The indication in 97% (144/148) of patients was to determine the presence of subclinical joint inflammation. 25% (37/148) of our patients had some degree of synovitis on ultrasound. 54% (20/37) had immunosuppression commenced or escalated. 55% (11/20) of these patients had an established diagnosis of an inflammatory arthritis. Ultrasound of the feet was requested in 11% (17/148) and one individual had immunosuppression commenced as a result of synovitis in the feet. In the RA group, DAS28 had a weakly positive correlation with PD score for hands and feet (R ¼ 0.14, P ¼ 0.02), and an even weaker correlation with PD score for feet alone (R ¼ 0.07, P ¼ 0.005). In the control group, DAS28 did not correlate significantly with either scores (R ¼ 0.46, P ¼ 0.22 for feet and R ¼ 0.5, P ¼ 0.25 for hands and feet). Conclusion: We found that DAS28 correlated poorly with objective evidence of inflammation as detected by US of the hands and feet in RA patients. Our results highlighted the problem with DAS28 values being significantly influenced by the patient's perception of pain; however this weak correlation was still significant as the active inflammation in the feet might have also contributed to the patients' reported outcomes. Further validation of our results in a larger study, including patients stratified based on the disease duration and symptoms might help understand which patient subgroups are more likely to have their disease activity significantly under-evaluated using DAS28 outcome measure. Background: Gout and hyperuricaemia have been associated with an increased risk of diabetes and cardiovascular disease. Gout commonly affects the foot with a predilection for the first metarsophalangeal joint and diabetes is frequently associated with foot ulceration. However there are limited studies that explore associations between altered mechanics in those with gout/diabetes. We aimed to determine whether plantar pressure significantly differed between patients with diabetes, gout and age-matched controls. Methods: Using a Tekscan pressure mat, peak plantar pressures and pressure time integrals were calculated for seven predetermined regions of the foot. Participants comprised: gout n ¼ 25, diabetes n ¼ 21, concomitant gout and diabetes n ¼ 17 and n ¼ 33 healthy age/ sex matched control subjects Results: Compared to controls, all patient groups demonstrated reduced heel, increased midfoot and reduced second metatarsal peak pressure. The diabetes and diabetes plus gout groups demonstrated increased first metatarsal peak pressures. Whereas the diabetes and gout group demonstrated increased hallux peak pressures and increased third to fifth metatarsal peak pressures compared to the gout group (all p < 0.05) ( Background: Bone marrow edema syndrome (BMES) of the foot and ankle is a rare non-traumatic syndrome, characterized by joint pain with weight bearing and diffuse reversible BME pattern on magnetic resonance (MRI) images. The aetiology of primary BMES remains uncertain. Ischaemia has been suggested as an initiating factor. Various studies show histological findings to include abnormal vascularity, edema and increased focal bone turnover. The purpose of this study was to assess the pattern of BMES over time in a cohort of patients and the benefit of a single dose of intravenous (IV) Zolendronic acid in this group. Methods: Retrospective analysis of 8 patients (mean age 51 years) diagnosed with foot and ankle BMES on MRI over a 5-year period up to 2016 using hospital records. The diagnosis of BMES was made following clinical and radiological assessment by excluding other causes of bone marrow edema such as fractures, systemic and local inflammation and infection. All patients had MRI and these images were interpreted by specialist musculoskeletal radiologists. Patients with risk factors for osteoporosis underwent bone mineral density scan (DEXA). Clinical and MRI evaluation was undertaken at 3 and 6 months to assess treatment response.
Results: Six patients (75%) patients were female and two (25%) were male with a mean age of 41.5 and 32.5 years, respectively. The average duration of symptoms was 14 months from the onset to diagnosis. The most common bone affected was the talus (75%) and multiple bones affected in 7 (87%) patients. All patients were given IV bisphosphonate as treatment. The mean time to resolution of pain in patients treated with Zolendronic acid (7 patients) was 2.4 months. One patient failed to attend follow-up and one patient had poor response to intravenous bisphosphonate requiring surgical intervention. Six patients (75%) showed clinical and radiological response (MRI) at 6 months following bisphosphonate therapy Conclusion: BMES is uncommon but must be considered by clinicians while evaluating patients with unexplained persistent foot and ankle pain on weight bearing, despite normal plain radiographs. There is no current guidance on the management of BMES. The only investigation which has been helpful is MRI scan of the affected area, which the clinicians should strongly consider while evaluating patients. Although we have demonstrated excellent response to IV bisphosphonate therapy in our case series of patients, there is a need for further good quality studies in the management of BMES. Background: Macrophage activation syndrome (MAS)/secondary haemophagocytic lymphohistiocytosis (sHLH) is a rare, self-perpetuating hyperinflammatory state with a significant mortality (8-25%). It most commonly occurs in rheumatic disease, malignancy and infection. It is diagnostically challenging, requiring a high index of suspicion where patterns of results rather than absolute values are key. Treatment includes steroids, IVIG, anakinra and etoposide guided by the HLH protocol.The histiocyte society set out MAS/sHLH diagnostic criteria (5 out of the following 8: fever, splenomegaly, cytopaenia, haemophagocytosis, ferritin !500 ng/ml, low natural killer cell activity, hypofibrinogemia, fasting hypertriglyceridemia and raised soluble CD25). Although high elevated ferritin (HEF) levels can be due to a wide range of causes, levels !10,000ng/ml are thought to be pathognomic of MAS/sHLH and it should be actively excluded. We conducted a retrospective evaluation of all patients with HEF over 17 months to assess whether MAS/sHLH was actively excluded. Methods: Between April 2013 and Sept 2014 laboratory records were searched for ferritin values !10,000ng/ml. Case notes were reviewed to examine demographic and diagnostic details, admission to critical care and status post-hospital discharge. We also examined available laboratory results against HLH-2004 diagnostic criteria. Trust permission for service evaluation was obtained. Results: 38 ferritin levels !10,000ng/ml from 29 patients (Range 10,108-61,689ng/ml). 25 patient records were reviewed [60% male, median age 63 years (range 17-88)]. 32% were admitted to critical care and 52% survived hospital admission. The primary diagnoses were 40% haematological malignancy, 16% non-haematological malignancy, 8% liver disease, 12% unknown and 20% miscellaneous diagnosis (e.g. organ failure and Guillain-Barre). Apart from the single patient with MAS diagnosis, none of the other audited patients were assessed for sHLH/MAS despite much of the diagnostic information being available (100% had blood count, 92% fibrinogen level, 92% temperature documented, 68% assessed for splenomegaly, 32% bone marrow aspirate,16% had triglycerides) Conclusion: There needs to be a high index of suspicion for sHLH/ MAS in the sick medical patient where the hyperinflammatory state is more amenable to treatment when started early. This retrospective evaluation shows HEF (ferritin !10000 ng/ml) did not trigger an MAS/ sHLH assessment in patients who subsequently went on to have poor outcomes and high mortality rates. Notes assessments suggested MAS could have been present in a number of cases but formal MAS screens or documentation of consideration of MAS were absent: the diagnostic criteria rely on common tests which in most cases were done but not considered in an MAS framework. HEF is associated with a poor patient outcome and should mandate the exclusion of sHLH/ MAS. There needs to be an increased awareness of sHLH/MAS amongst physicans (especially in haematology, rheumatology, infectious diseases, intensive care) and prospective study of the clinical significance of HEF. Disclosure statement: The authors have declared no conflicts of interest.
IMPROVING THE MANAGEMENT OF GIANT CELL ARTERITIS: A REVIEW OF THE CARE PATHWAY FOR PATIENTS WITH SUSPECTED GIANT CELL ARTERITIS IN A DISTRICT GENERAL HOSPITAL
Alex Hunter, Ravi Shah, Fang En Sin, Monica Ragheb, Sian Griffith, Ursula Davies, Raad Makadsi and Warren Shattles Rheumatology, East Surrey Hospital, Redhill, UNITED KINGDOM Background: Giant cell arteritis (GCA) requires prompt diagnosis and treatment to prevent irreversible neuro-ophthalmic complications. Misdiagnosis leads to unnecessary treatment with high dose glucocorticosteroids (GC) and their associated complications. The British Society of Rheumatologists (BSR) Guideline emphasizes early recognition of symptoms and prompt treatment when index of clinical suspicion is high. At East Surrey Hospital (ESH), we noted that some patients were not managed in accordance with BSR guidelines, resulting in inappropriate diagnosis or management. Additionally, there is no existing care pathway for patients with suspected GCA to be referred to Rheumatology and for Temporal Artery Biopsy (TAB), often resulting in delayed care provision, or unnecessary use of health care resources. This study aims to audit the management of patients with suspected GCA against BSR guidelines. Additionally, it aims to evaluate patients' journey, to identify delays or inefficiencies within the management pathway, in order to initiate improvements the service. Methods: Case notes of patients seen in ESH with suspected GCA between March 2015 and June 2016 were reviewed retrospectively. Cases were identified through keyword search on hospital discharge letters and Rheumatology clinic letters. Results: Case notes of 39 patients (13 male, 26 female) were analysed. Of those presenting with suspected GCA, 31% fulfilled ACR classification criteria for GCA. Concordance with BSR guidelines: 74% of patients were started on prednisolone at presentation and of these 13% had a TAB within 7 days. 36% were seen by a Rheumatologist within a week of presentation. Of those referred for a TAB 11% were performed within a week. Care Pathway: The majority of patients (69%) first presented to GPs. Despite this, only 46% of referrals to rheumatology were by GPs. Other referral sources included the Acute Medical Unit (28%) and ophthalmology (5%). 59% were seen by a Rheumatologist within 7 days from referral date. 36% had a final diagnosis of GCA. Conclusion: The small proportion of patients with a final diagnosis of GCA highlighted that early Rheumatology assessment is important to minimize unnecessary TAB and high dose GC. Additionally, the lack of a structured care pathway and a standardized referral system for GCA meant that a large proportion of patients had delay in the diagnosis, inappropriate treatment with high GC, and unnecessary TAB. In light of this, a GCA pathway was implemented to enable rapid access to Rheumatology in patients with suspected GCA. The on-call team was advised to redirect any GP or A&E referrals with suspected GCA to the rheumatology on-call bleep and patients will be assessed and managed by the rheumatology on-call Registrar or Consultant within 24 hours. We intend to re-audit the impact of these new implementations in 2017. Background: Limitations in methods of monitoring disease activity in the idiopathic inflammatory myopathies (IIM) may contribute to poor outcome. Cardiac involvement occurs in up to 75% of IIM but is under recognized and often subclinical. We investigated the role of a panel of serum muscle damage markers [creatine kinase (CK), cardiac troponin T (cTnT), cardiac troponin I (cTnI) and creatine kinase-MB (CK-MB)], thought to be differentially indicative of damage to different muscle types, in quantifying disease activity and identifying cardiac involvement in IIM. Methods: Adults with confirmed IIM (n ¼ 43) were evaluated using the International Myositis Assessment and Clinical Studies Group disease activity Core Set Measures (CSMs), and by measurement of serum CK, cTnT, cTnI and CK-MB. Cardiac involvement was assessed using the cardiac domain of the Myositis Disease Activity Assessment Visual Analogue Scales (cardiac-MYOACT). Eight patients returned for further review after six months. Spearman's ranked correlation was used and differences between those with active and inactive IIM (using the Rituximab in Myositis study definitions) were examined using logistic regression.
Results: Disease subgroups included dermatomyositis (47%), polymyositis (37%), anti-synthetase syndrome (12%) and connective tissue disease-overlap (5%). The mean age was 53 years (SD 16 Levels of cTnT were significantly higher in active compared to inactive disease (median 220 versus 22 ng/L, p ¼ 0.009). There were nonsignificant trends towards increased CK and CK-MB, but no difference in cTnI levels between these groups. In those with a normal CK (n ¼ 26), cTnT was increased in 39%, cTnI in 12%, and CK-MB in 19%. None of these cases had a cardiac-MYOACT score >0. Using cTnT, cTnI or CK-MB instead of CK within the active disease definition failed to identify additional cases. No marker reliably predicted a cardiac-MYOACT score >0. Where this was >0 (n ¼ 6), raised CK and cTnT levels were found in all whereas cTnI and CK-MB levels were raised in 33%. During follow-up 67% of those with a raised cTnI (n ¼ 6) were felt to have cardiac involvement. In such cases, there was a trend towards higher cTnT levels than in those with a normal cTnI (median 121 versus 22 ng/L, p ¼ 0.134). Conclusion: Using cTnT and CK-MB may improve accuracy when quantifying IIM disease activity. We did not identify a marker that was reliably predictive of cardiac involvement, although very high levels of cTnT in association with a raised cTnI may be indicative. Background: Hip fractures in the elderly lead to an increased risk of mortality, poorer quality of life and increased morbidity. Benzodiazepine (BNZ) use is associated with hip fracture, consequently Z-drugs are fast becoming the physician's hypnotic prescription of choice yet data on their use are limited. This study aims to compare the risk of fracture between Z-drugs and BNZ medications, and determine if this is attenuated over longer use. Methods: Medline and SCOPUS up to 11 May 2015. Data sources were case-control and cohort studies of patients aged over 65 with a hip fracture. Each included study was quality-assessed. A pooled relative risk of hip fracture was calculated using the generic inverse variance method, with a random effects model. The length of hypnotic usage was used as a subgroup. The primary outcome measure of this study was risk of hip fracture in elderly patients associated with BNZ or Z-drug prescription. Results: BNZ and Z-drug use were significantly associated with an increased risk of hip fracture (RR ¼ 1.52, 95% CI 1.37-1.68; and RR ¼ 1.71, 95% CI 1.45-2.01). New and short term use of BNZ and Zdrugs was associated with the greatest risk of fracture (RR ¼ 2.40, 95% CI 1.88-3.05; and RR ¼ 1.67, 95% CI 1.27-2.18). Conclusion: There is clear evidence that both BNZ and Z-drugs are associated with an increased risk of hip fracture, and there is little difference between them. Patients newly prescribed these medicines are at the greatest risk of hip fracture. Clinicians and policy makers need to consider the increased risk of fallings and fracture particularly amongst new users of these medications. Disclosure statement:The authors have declared no conflicts of interest. Background: Enabling Self-management and Coping with Arthritic Pain using Exercise, ESCAPE-pain, is a rehabilitation programme for people with knee and/or hip osteoarthritis (OA). It delivers guideline core recommendations (information, self-management advice, exercise) that reduce pain, improve function, is cheaper and more costeffective than usual care and participants value its benefits. The programme is usually delivered in physiotherapy departments. However, financial and logistical constraints limit the number of people able to access the programme. Delivering ESCAPE-pain in community centres would increase accessibility, reach and provide better on-going support, and many more people would benefit. This study wanted to establish if delivering ESCAPE-pain in community leisure centres was feasible, effective, acceptable and sustainable. Methods: The programme (http://www.escape-pain.org/) was supervized by 2 physiotherapists in 3 Inner London leisure centres. Briefly, participants attended 12 sessions (2 sessions/week for 6 weeks) each comprised of a 25-minute education component and 45-minute exercise component. The education is a supervisor-guided theme discussions giving information, self-management and coping advice and incorporates behavioural change techniques. The exercise is an individualized, progressive regimen circuit that helps participants come to appreciate exercise is a safe, effective self-management strategy that reduces the impact of OA. Pain, function and quality of life (Knee or Hip Osteoarthritis Outcome Score, K/HOOS), anxiety and depression (Hospital Anxiety and Depression Scale) were measured before and after the programme. Participant experiences were evaluated using semi-structured interviews. Results presented as (mean change; 95% confidence interval; p-value) Results: 146 participants were recruited, mean age 64 years. Approximately 75% of participants attended at least 75% of the programme (!8/12 sessions). No adverse events were reported. Clinical improvements were observed in pain (7.00; 4.57 to 9.43; p < 0.0001), function (7.57; 4.48 to 10.67; p < 0.0001), QoL (6.92; 3.95 to 9.89; p < 0.0001) and anxiety (1.77; 1.06 to2.48; p < 0.016). Participants were very satisfied with the programme and its outcomes, not only describing improvements in knowledge and symptoms, but also their confidence and attitude to exercise and understanding of the role of exercise in the management of OA: ''. . .I now have more movement and less pain. . .'', ''. . .it has helped me get back into regular exercise. . .'' and ''. . .I have gained more confidence and knowledge about my arthritis. . .'' A large majority (80%) planned to continue exercising at leisure centres after completing the programme. The leisure centres decided to run the programme permanently. Conclusion: Delivering ESCAPE-pain in community settings is feasible, safe, improves clinical outcomes, acceptable, sustainable and nurtures an exercise habit. It is a community-based programme capable of caring for the large and rapidly increasing number of people with chronic joint pain. The programme is now being delivered in leisure centres across the UK. Disclosure statement: The authors have declared no conflicts of interest.
INCREASING ACCESS TO COMMUNITY-BASED REHABILITATION FOR KNEE AND/OR HIP OSTEOARTHRITIS
DETERMINING FRACTURE RISK IN PATIENTS WITH A HISTORY OF RECURRENT FALLS: AN OBSERVATIONAL STUDY
Rachel Skelly 1 , Richa Sinha 2 and Marwan Bukhari 2 1 Medical student, Lancaster University and 2 Rheumatology, Royal Lancaster Infirmary, Lancaster, UNITED KINGDOM Background: Recurrent falls are a significant cause of morbidity and mortality in the general population. It is currently estimated that falls cost the NHS £2.3 billion every year. People aged 65 and over have the highest risk of falling. Approximately 5% of falls in the community among the older population result in a fracture or hospitalisation. Falls increase the risk of fractures and therefore prevention of fall prevention is paramount in preventing fractures. The FRAX tool is designed to predict fractures in vulnerable groups by using patient age and sex alongside other risk factors, including smoking and femoral neck bone mineral density. Our objective was to determine the predictors of fracture risk in a large observational cohort with a history of recurrent falls. Methods: Data were collected from 365 individuals who suffered recurrent falls between 2004 and 2016. The patients' age, gender, weight, medical history, lifestyle choices and dual-energy x-ray absorptiometry (DEXA) results were gathered. History of smoking, alcohol, family history of fracture, Rheumatoid Arthritis, bone mineral density (BMD) in both the lumbar spine and the femoral neck, height, weight, body mass index (BMI), gender, age at scan and steroid use were used as predictors. Univariate and multivariate logistic regression models were used to predict fractures in the cohort using the above explanatory variables. Results: 365 patients were included in the analysis. 198 (54%) had sustained a fracture, using the demographics shown in Table 1 . The mean age at scan was 70.28 years (SD 11.50) . Univariate analysis showed that bone mineral density of the lumbar spine is associated with fracture in this cohort. The multivariate analysis model also showed that the lumbar spine bone mineral density is a predictor for fracture in this recurrent falls cohort. Conclusion: The univariate analysis and multivariate analysis showed that bone mineral density of the lumbar spine is a predictor for fracture in this cohort. Femoral neck bone mineral density is not a predictor in this cohort. Therefore, the FRAX tool may underestimate the risk of fracture in this group. 279 Norwich Medical School, University of East Anglia, Norwich, UNITED KINGDOM Background: Social isolation is the lack of meaningful and sustained communication or interaction with friends, family and the wider community. It presents a major health and social challenge particularly for older people. Social isolation is associated with a number of adverse health effects including poor physical and mental health, maladaptive behaviours and an increased likelihood of institutionalization. Hypothetically, social isolation should decrease following total hip replacement (THR) or total knee replacement (TKR), through reduced joint symptoms and increased functional capability and physical activity. However, individuals may have considerable reluctance to be more socially engaged because of uncertainties around what they can and cannot do, about fear avoidance regarding damaging the joint replacement, or a reluctance to engage in activities due to psychological or emotional barriers after a long-period of chronic pain. However, very little has been reported on whether this occurs in the real-world. Accordingly, this study will determine the prevalence and trajectory of social isolation in people before and after THR and TKR in England.
Methods: The English Longitudinal Study of Ageing (ELSA) dataset, a prospective study of community-dwelling older adults, was accessed to identify people who had undergone a primary THR or TKR because of osteoarthritis. Social isolation was assessed through four domains: socializing in the community; holidaying; membership to community/ social groups and home-based isolation. The prevalence of social isolation was calculated and multilevel modelling was performed to assess the trajectory of these measures before joint replacement, within a two-year operative-recovery phase and a further two-year final follow-up. Results: The sample consisted of 201 people (114 post-THR/87 post-TKR). Seventy-six females and 125 males were analysed, with a mean age of 72.9 years (standard deviation: 10.7). Prevalence of social isolation, when measured between the four domains, ranged from 13% to 38% pre-operatively to 9% to 36% at the final post-operative follow-up. Social isolation was most prevalent for participation in community/social groups (36%; 95% CI: 27% to 45%), and least prevalent for home-based isolation (9%; 95% CI: 4% to 14%). There was no statistically significant change in any measure of social isolation between pre-operative to the final follow-up two years postjoint replacement (p > 0.05). Results were similar between people who underwent THR and TKR, with the exception being socializing in the community, where people post-TKR demonstrated greater social isolation in community activities compared to those after THR (p ¼ 0.02). Conclusion: Given the negative physical and psychological effects which social isolation can have on individuals, health professionals who treat people with osteoarthritis should be mindful of this health challenge for this population. Appropriate interventions should be available to address social isolation following joint replacement surgery, so people can maximize the health benefits to which THR and TKR can offer. Background: Kinesiophobia (fear of movement) is one of the most important factors that affects the success of rehabilitation in many diseases, especially orthopaedic ones. total knee arthroplasty (TKA) is a surgical operation where the articular surface of a musculoskeletal joint is replaced in order to to relieve pain and restore function to the joint after damage by arthritis or some other type of trauma. Degenerative osteoarthritis, rheumatoid arthritis, traumatic arthritis, tuberculosis arthritis, pseuriatic arthritis, haemophiliac arthritis and neurapthic arthropathy are among the well-known TKA indications. Tampa Kinesiophobia Scale (TKS) is a scale comprised of 17 questions and that has been developed to measure the fear of movement and re-injury. This scale has been used frequently in the literature, and the main fears are taken as fear of work-related activities, movement and fear of being injured again. The subject can take a score in the range of 17 to 68. The higher the score, the higher the level of kinesiophobia. In many studies, it is recommended that total score is used. TKS was developed in in 1991, and its Turkish validation was done in 2011. The aim of this study is to examine the kinesiophobia in patients who have undergone a single-sided TKA. Methods: We had 60 patients in this study. 45 patients had singlesided TKA, and 15 of them had single-sided radiographic grade-3 osteoarthritis (OA). We have registered the demographic data of patients, and evaluated their kinesiophobia using TKS. Obesity, depression, anxiety, previous joint surgical operation, diagnosed neuropathy, diabetes mellitus were used as exclusion criteria. Results: The mean age was 66.6 (56-74), and mean BMI was in the normal range. In 93.3% of the patients there was kinesiohobia, whereas in the patients with single-sided OA, this was found to be 26%. In our study, there is a statistically significant difference (p < 0.001) between the single-sided TKA patients and the ones with single-sided knee OA, showing the ones with single-sided TKA had more kinesiophobia. Conclusion: In the literature, there are limited studies indicating that starting to move at a later period after the surgery leads to kinesiophobia. We believe that with early rehabilitation after TKA, it is possible to have early treatment of kinesiophobia. Background: Shock waves are acoustic wave pulses, similar to ultrasound, they are characterized by very high pressure (up to 100MPa), growth of small and low tensile wave components. Shock waves has an effect on quite fundamental processes, loosening of tissue and it stimulates repair processes and improves microcirculation. Tissue that is exposed to shock waves, begins to synthesize of vascular endolethlial growth factor (VEGF). Sprawl of microvessel occurs under influence of VEGF, which leads to angiogenesis and neovascularization, consequently, restoration of blood supply to the tissue. Methods: C-reactive protein (CRP), lipids, liver activity enzymes and immunoparameters tumor necrosis factor (TNF) level, interleukin (IL-6) were evaluated in a model of experimental allergic arthritis (20 rabbits). Biochemical analysis of blood serum were determined with photometric method on biochemical analyzer NUMALAYZER PRIMUS (NUMAN, Germany), interleukins of serum were examined using the enzyme immunoassay analyzer HUMAREADER HS (NUMAN, Germany) Results: The study showed a sharp increase in non-specific markers of inflammation -TNF-a and IL-6, which is indicates the severity of the pathological process and an increase level of a marker of endogenous intoxication CRP, against the backdrop of increasing the titre of specific marker of rheumatoid arthritis -R-factor. Marked decrease in the level of cytokines were determined that indicates the acceleration of metabolic processes in the cells of the inflamed joint in experimental allergic arthritis when using the midfrequency shockwaves. Decrease in the level of inflammation indicates a significant decrease in the concentration of a marker of endogenous intoxication of CRP. Due to the use of shock waves chemical cells changes free radicals, which produce substances that inhibits pain. Thus, under influence of the midfrequency focused shock waves in the tissues of the inflamed joint is enhanced microcirculation, increases cell metabolism. Conclusion: The mid-range shockwave therapy reduces inflammation and activates cellular metabolism thereby contributing a partial improvement in the pathological conditions of the joints experimental animals experimental allergic patients with arthritis. Disclosure statement: The authors declare no conflicts if interest. Background: Osteoarthritis (OA) can negatively impact levels of physical activity (PA), although current advice advocates staying active to prevent joint-degeneration. We have previously observed no association between a clinical or self-reported diagnosis of lower limb OA and low impact PA levels in a cohort of older adults. Here we extended this analysis to consider associations between a radiographic diagnosis of lower limb OA and PA.
A RADIOGRAPHIC DIAGNOSIS OF PATELLOFEMORAL OSTEOARTHRITIS IS ASSOCIATED WITH ALTERED PHYSICAL ACTIVITY IN OLDER ADULTS
Methods: The study population comprised 69 men and 45 women from the Hertfordshire Cohort Study, who were also part of the UK arm of the European Project on Osteoarthritis (EPOSA). Participants had data on OA, at knee and hip sites, collected from face to face interviews and radiological examination of hip and knee joints, graded according to Kellgren and Lawrence (KL) . Approximately 2.5 years later GCDC tri-axial accelerometers, worn at the hip site for seven days, were used to measure day-to-day levels of physical activity as part of the Vertical Impacts on Bone in the Elderly (VIBE) study. Vertical acceleration peaks over 7 days, expressed in g units, were categorized into low (0.5 g<1.0), medium (1.0 g<1.5) and high (!1.5g) impacts. Acceleration peaks were calculated based on accelerations higher than the preceding and subsequent reading. All g values represent g over and above 1g from earth's gravitational force. Due to significantly skewed data differences between accelerometry peaks by OA status were assessed using a non-parametric test. Results: The mean (SD) age of participants was 75.3 (2.6) years in men and 75.4 (2.6) years in women. The relationship between knee osteoarthritis (OA) progression and changes in subchondral tibial bone structure has recently been recognized and various texture descriptors have been proposed to detect early stages of OA. However the application of such algorithms is largely dependent on the region of interest (ROI) selected within the subchondral bone area. Therefore, the appropriate selection of ROIs plays a crucial role for the significance of the analysis. Based on our previous work, the present study aims to a) investigate the potential of a combined bone micro architecture algorithm (BMA) as an efficient alternative to established OA descriptors, and b) to define the most significant ROIs for OA discrimination. Methods: 89 left and 64 right knee joint radiographs of Caucasian females were available, 66 cases and 86 controls. In contrast to our prior work which was limited to proximal tibia, the additional (and novel) effort is to investigate two regions in both condyles of the distal femur. The selected area of the proximal tibia involved a matrix of 3x8 ROIs, whereas a 2 Â 2 matrix was defined for each condyle of the distal femur. Bone Structure Value (BSV) and Shannon Entropy (SE) were calculated for each of the 32 ROIs, respectively. Based on these 64 variables, combinations of ROIs, both individually and in the context of other features and their descriptors, were systematically investigated using statistical and machine learning methods to identify the best performance for discrimination between case and controls. Results: In addition to the tibial changes, our results indicate that OA is also affecting the subchondral bone structure in femur condyles. By combining the BSV and SE, the odds ratio increased significantly from 3.08 (95% CI: 1.78-5.30) to 14.82 (95% CI: 6.69-32.83) when using 15 features, and to 39.75 (95% CI: 15.41-102.51) based on 10 features. By using the selected 10 features the accuracy was found to be 0.86, reflecting a significant improvement compared to the accuracy achieved when calculating a single mean value for the 3 Â 8 ROIs of the proximal tibia alone (0.62 vs. 0.86).
Conclusion:
The combination of subchondral ROIs of both femur condyles and the proximal tibia clearly improve the discrimination between OA cases and controls. The model can further be improved by incorporating shape descriptors and a full automation, exploiting recent advances in segmentation and/or landmarking. Moreover, our approach may also be of interest for alternative fields of research, in particular the investigation of BMA descriptors in osteoporosis. Disclosure statement: The authors have declared no conflicts of interest.
PROTEIN OXIDATION, NITRATION AND GLYCATION FREE ADDUCTS: BIOMARKERS FOR EARLY-STAGE DIAGNOSIS AND TYPING OF ARTHRITIS
Usman Ahmed, Paul J. Thornalley and Naila Rabbani Warwick Medical School, University of Warwick, Coventry, UNITED KINGDOM Background: Increased damage to proteins in the joint by oxidation, nitration and glycation is considered to contribute to the development of arthritic disease. Biomarkers related these damaging modifications may provide the basis for early-stage diagnosis and typing of arthritis. Proteolysis of oxidized, nitrated and glycated joint proteins releases corresponding amino acids into synovial fluid which exchange readily into plasma. We measured these trace level, damaged amino acids in plasma of healthy subjects and patients with early-stage osteoarthritis 285 CEL, N " -(1-carboxyethyl)lysine; CMA, N " -carboxymethyl-arginine; CML, N " -carboxymethyl-lysine; 3DG-H, 3-deoxyglucosone-derived hydroimidazolone; FL, N " -fructosyllysine; MG-H1, methylglyoxal-derived hydroimidazolone; DT, dityrosine; MetSO, methionine sulphoxide; NFK, N-formylkynurenine; 3-NT, 3-nitrotyrosine; hyp, hydroxyproline; CCP, cyclic citrullinated peptide.
(eOA), early-stage rheumatoid arthritis (eRA) and other self-resolving inflammatory joint disease (non-RA) and explored their application for diagnosis and typing of early-stage disease. Methods: Patients with knee joint eOA, eRA and nonRA, and healthy subjects with good skeletal health were recruited for the study (n ¼ 186). Venous blood samples were collected with informed consent and plasma prepared and analysed for oxidized, nitrated and glycated amino acids by quantitative liquid chromatography-tandem mass spectrometry. Data-driven machine learning methods were employed to explore diagnostic utility of the measurements. Ethical approval was sought and obtained from local ethics committees. Results: Glycated, oxidized and nitrated amino acids were detected in plasma of arthritic patients with characteristic patterns found in eOA, eRA, and non-RA, with respect to healthy controls. In early-stage disease, two algorithms for consecutive use in diagnosis were developed: disease-versus-healthy control, and classification as OA, RA and non-RA (Table 1 Background: An estimated 4.71 million people aged 45 and over have sought treatment for knee osteoarthritis (OA) in the UK, with this number predicted to grow to 6.5 million people by 2020. Structural changes of knee OA are the most common cause of disability in the UK; symptoms include pain, stiffness, crepitus, swelling and giving way, increasing the risk factor for falls. Medial compartment osteoarthritis (MCOA) has been found to be the most common form of OA and dynamic joint loading has been implicated in disease progression. It has been postulated that various load-bearing conditions alter kinematics and kinetic load and this has the potential to unevenly distribute load across articular cartilage surfaces. NICE guidelines have stipulated that conservative treatment methods, such as footwear for long-term self-management of knee osteoarthritis are a priority for research due to the prevalence of OA and the growing population. The objective of therapeutic footwear is to distribute load evenly across the knee joint by reducing the peak external knee adduction moment (EKAM) and knee adduction angular impulse (KAAI) by manipulating the vertical ground reaction force vector laterally to the knee joint centre and preventing exaggerated adduction of the tibia. The purpose of this review was to explore the literature in relation to footwear that have specific design features, aimed at providing symptom relief and reducing EKAM and KAAI in individuals living with MCOA. Additionally taking in consideration the needs, expectations and perspectives of the at risk population. Methods: Systematic searches were carried out in July 2016, using the EBSCOhost research database (SPORTDiscus, Medline, CINAHL and Academic search premier), Pubmed and Web of Science. Critical appraisal was performed using the validated Downs and Black appraisal tool. Results: Fifteen articles satisfied the inclusion criteria. Overall, articles appraised were scored fair to moderate methodological quality. All footwear revealed variable reductions of first peak EKAM and KAAI when compared to control shoes that were selected due to their stable and supportive nature. All research that compared shod conditions to barefoot walking found that shoes increased first and second peak Background: Tissue engineering (TE) strategies using mesenchymal stem cells (MSCs) offer significant potential as a therapeutic approach for treating OA. Local injections of MSCs are currently undergoing Phase IIb/III clinical trials in patients with knee OA. Recently, strontium was shown (SEKOIA study) to slow progression of OA, reduce pain, improve patients' mobility and reduce joint space narrowing. However, the link of increased cardiovascular risk with strontium precludes its use as a first-line disease-modifying osteoarthritis drug (DMOAD) for patients with knee OA. This study examined whether strontium affected osteogenic differentiation of cytokine modulated MSCs and therefore has a potential role as a bioactive molecule for incorporation into future TE strategies for OA. Methods: Human bone marrow stromal cells (HBMSC) were obtained from patients undergoing fractured neck of femur repair (n ¼ 3) following ethical approval and informed consent. Cells were cultured in basal media [alpha-modified Eagle's medium (alpha MEM) þ1% penicillin/streptomycinþ10% fetal calf serum], grown to confluence and seeded at 1 Â 10 4 cells per well in 24 well plates in either basal or osteogenic (basalþascorbateþdexamethasone) media, with or without the inflammatory cytokines IL-1 beta (10ng/ml), IL-6 (100ng/ml) and TNF alpha (10ng/ml). Strontium was added to cultures (except controls) at final concentrations of 0.1mM, 1mM or 10mM. Cells were cultured for 7 days, with media changes every 2-3 days. Cell viability was confirmed using cell tracker green and osteogenic differentiation using histological assessment of alkaline phosphatase (ALP) and biochemical assays for ALP and DNA content. Assay results were analysed using one way ANOVA to allow comparison across different culture conditions. Results: Strontium had no adverse effects on the growth of HBMSCs. Optimal cell growth was observed at 0.1-1mM concentrations of strontium. Under control conditions, IL-1 beta produced an additive osteogenic effect, as did IL-6 to a lesser extent. TNF alpha exerted a modest inhibitory effect. This was demonstrated by ALP histochemistry and confirmed through measurement of ALP specific activity. The additive osteogenic effect of IL-1 and IL-6 persisted when strontium was added to the cultures and was most marked at the 1mM concentration. Conclusion: When low concentrations of strontium were added to cytokine modulated HBMSC cultures, the additive osteogenic effects of IL-1 and IL-6 seen in control experiments became more pronounced. Studies in unselected versus Stro-1 selected MSCs will be required to investigate this observation further. Additional in vitro studies in cytokine modulated MSCs will help to clarify whether increased osteogenic differentiation of MSCs in the presence of inflammation contributes to strontium's beneficial effects in OA. The current studies indicate, future TE strategies for OA could then incorporate strontium as a bioactive factor either within a scaffold or delivered in the cell suspension. Background: Although published standards for quality of care for young people (YP, 10-24 years) exist, service priorities valued by YP with chronic rheumatic diseases may differ from generic standards. Unfortunately, evidence base for best practice for YP with rheumatic diseases across this age range is limited and their needs are often not identified. In order to accurately monitor quality and ensure optimal outcomes, it is essential to identify areas for service improvement using a developmentally and specialty appropriate toolkit. This project aims to develop a toolkit, using a patient-centred approach, that can define and benchmark good clinical practice for YP with chronic rheumatic disease. Methods: This was a mixed-methods study. Phase 1 identified 25 candidate criteria relevant for YP rheumatology from previous research and standards. Phase 2 discussed these criteria using one-to-one interviews and focus groups (FGs) with YP (N ¼ 38; median age¼19; range¼15-24; 82% female) and YP ranked each criterion in order of priority. The proposed toolkit was evaluated by healthcare professionals (HCPs; N¼22) via an on-line survey and a consensus meeting during phase 3. The toolkit was simplified from 25 to 17 criteria with !80% agreement among HCPs. Phase 4 ensured the toolkit's geographical relevance across the UK by refining it using FG discussions with YP from Sheffield, Northampton, and Newcastle (N¼21; median age¼18; range¼11-24; 57% female). Analytic hierarchy process was used to assign weights and scores to each criterion based on their relative importance. YP's satisfaction with the final toolkit and agreement with how it is scored were assessed using interviews (N¼19; range¼17-24; 70% female) and 5-point scales in phase 5. Results: The final toolkit included 17 service criteria, which were grouped into four main categories: assessment and treatment; information and involvement; accessibility and environment; and transition support. Each category was scored out of 100 points and was also assigned relative weights, which were 30%, 24%, 23%, and 23%, for categories 1, 2, 3, and 4, respectively. The final toolkit score is the sum of the points from individual categories multiplied by their weight. YP thought the toolkit was comprehensive and differentiated well between high and low priority criteria (M satisfaction ¼4.52, SD satisfaction ¼0.56; M agreement ¼4.03, SD agreement ¼0.54). Conclusion: We employed a rigorous multistep approach to develop a toolkit that clearly identifies aspects of care that are valued by YP and are considered valid by HCPs. Data collected using the toolkit can benchmark quality of care and compare performance across different centres, which can help departments assess what standards they should aspire to and reduce variations. In addition, the toolkit can facilitate commissioning and help with leveraging resources for quality improvement activities. The next phase will scope current services against the toolkit to assess its validity, reliability, and feasibility. Disclosure statement: The authors have declared no conflicts of interest. Background: It is unclear how to measure functional ability in adolescents with JIA. The proxy-completed Childhood Health Assessment Questionnaire (P-CHAQ) is validated for this age range but may not be developmentally appropriate. The adolescent CHAQ (A-CHAQ) has not been validated. In adolescent-specific and adult clinics post-transfer, the Health Assessment Questionnaire (HAQ) is completed. This tool would be preferable to capture functional ability during the transfer process. However, the comparability of these three measures is unclear. The aim of this study was to assess the comparability of the P-CHAQ, A-CHAQ and HAQ in a population of adolescents with JIA at initial presentation to rheumatology. Methods: At initial presentation to rheumatology, a subset of adolescents recruited to the Childhood Arthritis Prospective Study (CAPS) self-completed the A-CHAQ and HAQ, with proxies completing the P-CHAQ. Scores at baseline were compared using Bland-Altman plots, univariate and age and sex-adjusted linear regression models. Differences in improvement from baseline to one year were assessed via univariate and multivariate linear regression models, adjusted for age and sex. Results: At baseline, 94 adolescents had complete data on all three tools. Of these, 51 also had complete data at one year. The median age at diagnosis was 13 years (IQR 12 to 15) and 61% were female. Median disease duration at diagnosis was seven months (IQR 5 to 14) and the most common subtype was oligoarticular JIA (40%). Median baseline HAQ (0.5) was marginally lower than both CHAQ scores (both 0.6), although this difference was not clinically significant. The highest agreement at baseline was between the two adolescent-completed tools (94%) and lowest between the P-CHAQ and A-CHAQ (87%). After adjustment for potential confounders, all baseline scores were statistically and clinically similar (smaller than 0.125 point difference). Over the first year following initial presentation, improvements in all scores were also statistically and clinically similar (Table 1) . Conclusion: There was good concordance and similar associations between the P-CHAQ, A-CHAQ and HAQ both at initial presentation to rheumatology and improvement over the first year in adolescents with JIA. The strong relationship between the HAQ and either CHAQ tool indicate the utility of HAQ in adolescents with JIA. 
COMPARABILITY OF PROXY, ADOLESCENT AND ADULT MEASURES OF FUNCTIONAL ABILITY IN ADOLESCENTS WITH JUVENILE IDIOPATHIC ARTHRITIS
EARLY CLINICALLY INACTIVE DISEASE AND LONG-TERM OUTCOMES IN JUVENILE IDIOPATHIC ARTHRITIS
Stephanie J. W. Methods: Children with oligoarticular, rheumatoid factor negative or positive polyarticular JIA recruited before January 2011 to the Childhood Arthritis Prospective Study, a UK multicentre inception cohort, were selected. At one year following initial presentation, children were classified: CID Wallace's preliminary criteria and cJADAS10, CID Wallace's preliminary criteria only, CID cJADAS10 only and no CID. CHAQ and CHQ scores and the absence of limited joints to five years were compared between groups using multivariate zero-inflated negative binomial, linear and logistic regressions, respectively. Results: Of 832 children included, 70% were female and oligoarticular JIA was the most common subtype (68%). At one year, 21% had achieved CID on both tools, 7% on Wallace's preliminary criteria only, 16% on cJADAS10 only and 56% on neither tool. Compared with children who had active disease at one year, those that had achieved any state of CID had higher odds of no limited joints to five years (odds ratios): Both: 4.8 (95%CI 3.1, 7.3), Wallace only: 4.0 (95%CI 2.1, 7.7), cJADAS10 only: 2.2 (95%CI 1.4, 3.4). However, children that had achieved CID on Wallace's preliminary criteria had similar CHAQ and CHQ scores to those that had not achieved CID (p ¼ 0.602 and p ¼ 0.975, respectively). In contrast, children that had achieved CID on the cJADAS only or both tools had at least 31% lower CHAQ scores, three times the odds of zero disability and four points higher on the CHQ (Table 1) . Conclusion: Treatment strategies targeting both inflammation and patient global wellbeing may be superior to those purely targeting inflammation in terms of preventing poor long-term functional ability and psychosocial health. Disclosure statement: The authors have declared no conflicts of interest.
WHAT YOUNG ADULTS WANT FROM A YOUNG ADULT RHEUMATOLOGY SERVICE
Michaela Fay and Martin A. Lee Rheumatology, NUTH, Newcastle-upon-Tyne, UNITED KINGDOM Background: Transition from paediatric to adult health care is a complex process shaped by interpersonal as well as organisational factors. Health care transition also tends to coincide with other major events in the life of a Young Adult (YA) such as leaving school, moving away from home and gaining greater independence. These changes add complexity to the requirements YAs with long-term conditions have of a health service. Health care services should be designed to make YAs feel welcome, adequately informed and empowered to be involved in healthcare decisions. Feedback from patients who have used local YA/transitional care services suggests that these clinics fill a gap in the health care system. Methods: YAs, aged 16 to 24, who were currently receiving care for Juvenile Idiopathic Arthritis (JIA) were invited to participate in focus groups or, alternatively, individual face-to-face or telephone interviews aimed at local service development. These focus groups or interviews were led by a social scientist with experience in qualitative research. The focus groups and interviews explored the YA's experience of transition from paediatric to adult rheumatology services, their opinions on how this process could be improved or made as smooth as possible, service development and what YAs with long-term conditions such as JIA need from a health care service so that it works for them. Results: YAs seek active involvement and decision-making in their health care and condition management. They feel well looked after in a context that allows them to normalize their health care needs while still providing them with guidance. YAs described their wishes for a transitional, age-specific service in terms of a) the interpersonal dimensions of the care they receive, b) the physical environment in which they are seen, and c) service structures that allow them to lead as normal a life as possible. Conclusion: The qualitative research that was undertaken suggests that YAs living with JIA have a particular set of healthcare needs that neither paediatric nor adult services fully address. A YA specific health care service should therefore take into account the wider context and complexity of changes YAs that go through at the time of transition. If this is done effectively, the potential to lose patients who might otherwise fall through the net may be reduced, thereby potentially improving health outcomes. Although the focus groups and interviews focused on YAs with JIA, the findings could equally apply to YAs living with other long-term conditions. Disclosure statement: The authors have declared no conflicts of interest. Disclosure statement: The authors have declared no conflicts of interest. Background: There are mixed reports as to whether juvenile idiopathic arthritis (JIA) patients have impaired psychological health when compared to healthy children or not. Additionally, this has never been explored in a purely adolescent population of JIA patients and healthy adolescents. Methods: 135 JIA patients aged 13-18 years were recruited from University College Hospital, London and 73 age and gender matched adolescent healthy controls were recruited from local high schools. All participants gave informed consent. All participants completed a questionnaire pack assessing anxiety (State-Trait Anxiety Inventory), low mood (Short Mood and Feelings Questionnaire -Child Version), stressful life events (Coddington Life Events Scale), resilience (Resilience Scale) and well-being (Warwick and Edinburgh Mental Well-being Scale). For JIA patients, disease activity measures were also recorded on the same day of questionnaire completion. Data were analysed using the Spearman's Rank Correlation Coefficient, MannWhitney and Chi squared. Results: Demographic, psychological and clinical data for adolescent JIA patients and adolescent healthy controls are summarized in Table  1 . We found that JIA patients had significantly lower stressful life events scores (p < 0.05) than healthy age and gender-matched adolescents (Table 1 ). There were no other significant differences between JIA patients and healthy controls for depressive symptoms, anxiety, well-being and resilience scores. There was no significant difference between the proportion of patients and healthy adolescents scoring over the Mood and Feelings Questionnaire cut-off for probable depression (>8 points). Conclusion: We found adolescents with JIA have the same levels of depressive symptoms, anxiety, resilience and well-being as healthy adolescents, disproving the hypothesis that teenagers with JIA have worse psychological health than their healthy peers. Indeed, JIA patients experienced lower levels of life event stress than healthy adolescents, though this may be because of the significant lifestyle limitations experienced as a result of their disease. Disclosure statement: The authors have declared no conflicts of interest. Primary research comprises majority of this review. There appears to be reasonable quality evidence to support the use of IA steroid injections in JIA, leading to Grade A recommendations for use. It has been reported triamcinolone hexacetonide is superior to triamcinolone acetonide. Prednisone was most often used in patients with RFpositive polyarthritis and systemic arthritis. Methotrexate and CS usage together are frequent regardless of presenting disease features. There were systematic reviews regarding use of IA steroid, and comparison of DMARDS to conventional treatment. Paediatric rheumatologists' personal definitions of low-dose, long-term corticosteroid therapy vary within a wide range. Conclusion: There is a good body of reasonable quality evidence for the use of IA steroid injections in children with JIA, however there is no data to confirm whether the technique is disease modifying in the long term. Because of a lack of controlled trial data, it remains unclear whether multiple IA injection are more effective and/or less toxic than intravenous boluses, intra-muscular injections or oral steroid regimes to induce remission or treat a flare of established polyarticular JIA. In general, this literature review identified the paucity of evidence regarding the use of systemic steroids. There is evidence that children with systemic JIA respond to systemic corticosteroids, however there were no tested standardized dosing regimens for either induction or maintenance treatments or for tapering doses of steroids. It appears that there is a widespread variation in use of steroids among different clinical settings and centres. A randomized controlled trial of different CS regimes for induction of remission in JIA is indicated, to inform future guidance for CS use in children with JIA. Disclosure statement: The authors have declared no conflicts of interest. Background: Smartphones can facilitate collection of temporally-rich self-reported data, and have proven to enable large recruitment. However, their viability to support epidemiological research is uncertain due to concerns about selection bias and unsustained engagement. We examined representativeness and engagement over time of participants in the first six months of Cloudy with a Chance of Pain, a UK smartphone-based study investigating the link between the weather and chronic pain. Methods: Between 20 January and 29 February 2016, we recruited UK residents of 17 years or older with chronic pain who owned a smartphone. Participants received prompts from an app developed by uMotif, which they used to daily report the severity of ten pain-related symptoms. Per day, we labelled participants as engaged if they completed any of the ten symptoms. We then clustered them according to their engagement over time using a mixture of firstorder hidden Markov models. Representativeness was assessed by comparing age and gender between clusters, and to participants in a 2006 survey-based chronic pain study [mean age, 49.9 (SD 17.4); 56% females]. Results: Of 7129 people who registered to participate, 6370 provided valid baseline data and recorded at least one symptom. We identified four clusters of engagement (see Table 1 ), with 39% of participants assigned to the Low engagement cluster, and 36% engaging at least moderately throughout the six months. From High to Low engagement, participants were engaged in the study for a median of 175, 88, and 8 days, respectively; Tourists tended to be engaged for one day only. Highly engaged participants were more likely to be older and female. Compared another study population, our sample seemed representative in terms of age, but comprised a greater proportion of women. Conclusion: Cloudy with a Chance of Pain recruited a large sample of people with chronic pain. Over one in three participants engaged in smartphone-based symptom reporting for at least 50% of days in the first six months. While there may be selection bias towards older females, our study suggests that smartphones could provide a viable alternative to traditional data collection methods. 299 
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ADOLESCENTS WITH JUVENILE IDIOPATHIC ARTHRITIS EXPERIENCE LOWER LEVELS OF LIFE EVENT STRESS THAN HEALTHY ADOLESCENTS
THE USE OF CORTICOSTEROIDS IN CHILDREN WITH JUVENILE IDIOPATHIC ARTHRITIS: A LITERATURE REVIEW AS PART OF THE SIRJIA STUDY
Samundeeswari
PRESCRIBING PATTERNS IN JUVENILE IDIOPATHIC
PONCET'S ARTHRITIS: A FORGOTTEN ENTITY
Saptha Nair 1 and Damodar MakkuniNR46XU, 2 1 Acute Medicine and 2 Rhuematology, James Paget University Hospital, Great Yarmouth, UNITED KINGDOM Background: Poncet's disease or tuberculosis rheumatism is a rare aseptic form of arthritis observed in patients with active Tuberculosis. It was first described by Antonin Poncet in 1897, thought to be caused by an immune hypersensitivity response to tuberculoproteins that produces an inflammatory reaction in joints. Patients tend to present as Oligo or poly articular arthritis and the focus of infection is often extrapulmonary. There is poor awareness of this condition in the low TB endemic areas. Methods: A 55 year old Caucasian Engineer presented with acute onset of polyarthritis and neck pain following an episode of flu like illness. He had swelling of his knee, ankle and MCP joints. Initial bloods showed CRP of 316 with negative RF, AntiCCP, ANA and ANCA tests. Initial CXR showed no abnormal findings. The X-rays of his hands and feet showed no evidence of erosive disease. The synovial fluid aspirate from the knee joint was negative for crystals and gram stain. Also the culture revealed no growth. Reactive arthritis was suspected and he was started on a high dose steroids that relieved his symptoms temporarily but the joints flared up again when the steroid dose was tapered. He was then started on methotrexate but 6 weeks later he represented with night sweats, weight loss and a dry cough. The arthriits remained very active despite MTX and 20mg prednisolone, Results: A CXR was repeated and this time showed a right hilar mass; CT thorax revealed suprasternal and mediastenal lymphadenopathy and a small consolidation on the right lower lobe. Histopathology from the right supraclavicular node biopsy confirmed necrotic granulomatous disease consistent with mycobacterium; ZN stain also came back positive. He was HIV and Hepatitis B and C negative. Patient was started on anti-TB treatment and the MTX was discontinued. He made an excellent recovery and the arthritis went in to remission after starting the AKT. He was unsure of BCG vaccination and there was no obvious vaccination scar. Conclusion: This is a rare presentation of an extrapulmonary tuberculosis in a patient without any obvious risk factors for TB. He had never been to a TB endemic area or had family members who suffered from the disease. There is no direct bacterial invasion into the joint therefore synovial fluid culture is often negative. Unlike other reactive arthritidis antibiotic therapy seems to improve the joint symptoms, as noted in our case. The lack of response to traditional DMARDs and steroids in a patient with seronegative non-erosive arthritis should raise the suspicion of this rare condition and a delay in diagnosis may lead to a more disseminated TB infection with disastrous consequences. With the resurgence in extrpulmonary TB due to the use of potent immunosuppressive medications like biologics, it's important to remember this rare form of reactive arthritis. Disclosure statement: The authors have declared no conflicts of interest.
DOING MORE WITH LESS: EVALUATION OF THE CONDENSED FORMAT FIBROMYALGIA EDUCATION GROUP AT THE MINERVA HEALTH CENTRE
Samuel Naylor, Andrea Tebbutt and Elizabeth MacPhie Rheumatology Department, Lancashire Care NHS Foundation Trust, Preston, UNITED KINGDOM Background: The management of fibromyalgia (FM) requires a multidisciplinary approach, which should include a combination of pharmacological and non-pharmacological interventions. With limited resources available to rheumatology departments it is not possible to provide individually tailored self-management programmes. Many units now deliver self-management programmes to groups of patients with FM. In January 2013 the Rheumatology Department at the Minerva Health Centre established a Fibromyalgia Education Group delivered by occupational therapists and consisting of four sessions covering topics including: routine setting and pacing, managing stress and relaxation techniques, managing unhelpful thoughts and graded exercise. A significant frustration for the team was the high drop-out rate, with only around two-thirds of patients completing the course. With pressure on resources the group was reduced to a single session in May 2015. The aim of this project was to evaluate the condensed format. Methods: Patients attending the condensed FM group were asked to complete a questionnaire to assess their satisfaction with the group. This utilized Likert scales in response to a number of questions. Results were compared to responses from the extended group. Results: Satisfaction questionnaires were received from 42 patients who attended the condensed format and 49 patients who attended the extended format. The vast majority of patients attending the condensed format had a better understanding of their condition with 95% strongly agreeing or agreeing with this statement. This compared to 100% of patients who attended the extended format. 95% and 100% respectively of patients attending the condensed format felt that their views were taken seriously and that the professionals running the group had a good understanding about FM. 92% felt they were provided with enough coping strategies compared to 100% of patients who attended the extended format. However, only 26% no longer felt they would need to see their GP as frequently regarding their condition as they did before the course compared with 94% of patients who attended the extended format. Conclusion: Overall, analysis and feedback is encouraging. Condensing the FM course down to a single session does not appear to have affected the satisfaction with the group. However, only a quarter of patients felt they would see their GP less after attending the group. A previous frustration with the extended format was the high drop-out rate but this is obviously not a problem with the condensed format. The single session has allowed the team to deliver education about self-management to more patients with FM and to reduce the waiting list thus enabling the rheumatology team to make best use of available resources. Background: Complex regional pain syndrome (CRPS) is a persistent pain condition, of unknown aetiology, usually triggered by limb trauma. It is associated with sensory, motor, dystrophic and autonomic symptoms with no cure and little evidence for current treatments. Although relatively rare (incidence 5.46 to 26.2 per 100,000 person-years), it can lead to significant long-term disability and healthcare resource use. Currently, we are unable to define existing care. Establishing what this looks like internationally will help inform future patient and health professional service delivery, education initiatives, and content of clinical guidelines. The following questions were asked: How is care currently provided for patients with CRPS including referrals, wait times, re-referral services available, and depth of knowledge and expertise in the clinical community? What are clinician's CRPS treatment aims? What are the barriers and facilitators to practice: what helps and prevents clinicians achieving their treatment aims? Methods: Informed by published literature and expert practice, an online survey was created using survey software Qualtrics. Following University ethical approval, potential participants from the IASP Special Interest Group for CRPS, country specific Pain Societies and relevant health professional national/international organisations were recruited via the following routes: an advertisement with embedded link directing people to the survey posted on clinical network webpages; tweet with a link to the survey sent to professional special interest groups; a link on professional bodies' webpages alerting members to the survey and contacts within organizations disseminating survey information to their members. The survey was available between 1 September and 31 October 2016. A reminder was issued after two weeks. Results: 246 questionnaires were returned from 37 different countries. Clinicians (n ¼ 181, clinical/academics n ¼ 48) formed the majority of respondents (n ¼ 161 hospital based, n ¼ 77 community). They were relatively senior (n ¼ 49 5yrs in practice), working predominantly in Orthopaedics (41%), Pain (40%) and Rehabilitation (46%) specialities. The majority (68%) had seen 10 CRPS patients in the last year. 90% of all respondents stated they could identify the signs and symptoms of CRPS with little difficulty or no difficulty, 36% citing Budapest diagnostic criteria. The majority of patients were seen within 6 months of symptom onset. Treatment aims focused on pain and inflammation relief, education and normalisation of function. Perceived barriers to successful achievement of aims included: lack of clinical time, delayed referrals, patient related anxiety, severity of pain, treatment adherence and beliefs. Conclusion: These data provide new insights into routine CRPS practice. Reported treatment aims in this well informed survey population are in line with current clinical guidelines, but perceived service delivery and patient related issues potentially reduce clinical effectiveness and provide target areas for future interventions. Data analysis is ongoing and will be reported subsequently. Disclosure statement: The authors have declared no conflicts of interest. 
CURRENT CARE AND CLINICAL CHALLENGES IN THE TREATMENT OF COMPLEX REGIONAL PAIN SYNDROME
Sarah
INTEGRATED PAIN ASSESSMENT AND SPINAL SERVICE IN WEST BERKSHIRE SUCCESSFULLY DELIVERS IMPROVED OUTCOMES FOR MUSCULOSKELETAL PAIN
Background: The Integrated Pain and Spinal Service (IPASS) in West
Berkshire is a new service set up to support patients in managing musculoskeletal (MSK) and spinal pain. This is to reduce unnecessary referrals to secondary care. Since its inception in September 2015, IPASS has provided timely access to a multi-disciplinary team of specialists, delivered personalized treatment plans, and demonstrated the potential to be cost-saving when compared to current standard-ofcare. Methods: In 2014 clinicians from the Acute Trust (Royal Berkshire Foundation Trust), Community Trust (Berkshire Healthcare Foundation Trust), primary care physicians, commissioners and patients came together to address the problems of increasing outpatient activity for pain related conditions and the associated management of them. The recommendations from this group led to the development and enhancement of the already established Community Spinal Service into the Integrated Pain and Spinal Service (IPASS). All GP referrals for patients with general pain or spinal pain (excluding red flag patients) are now referred to the Pain or Spinal areas of IPASS instead of secondary care. Patients with general pain for longer than 3-6 months with no medically treatable pathology found after investigation are referred to the pain management part of IPASS. Patients with acute/ sub-acute spinal symptoms who may require further investigation or possible medical/surgical intervention are referred to the spinal part of IPASS. Results: Prior to IPASS, waiting times were in excess of 7-9 months for 1-to-1 physiotherapy and psychology assessments, and 6 months for a group programme. The average waiting time across multiple services is now 3.4 weeks and 92% of patients are seen within 6 weeks. It is forecast that IPASS will reduce multiple attendances linked with pain by at least 50% each year and that related day case procedures could be reduced by 5%. The investment in Year 1 is £343,451 and gross saving is £277,826. Feedback on the service has been very positive with 95% of patients remarking that the group sessions were very helpful in learning skills to manage pain. Everyone agreed that they had taken away something of lasting value and agreed that they are now much more confident having attended an IPASS session. Conclusion: The IPASS in West Berkshire provides a solution to most common source of pain which is musculoskeletal (MSK) and the goal of treatment is to successfully manage these conditions to improve functioning and quality of life. IPASS is a new service provision in the local health economy to manage these conditions successfully. It will reduce the financial burden of MSK pain which has increased 20% due to rising outpatient attendances across a number of specialist services. Background: Recent studies suggest that proton pump inhibitor (PPI) use is associated with risk of osteoporosis. The aim of this study was to investigate the relationship between PPI use and development of osteoporosis in scleroderma (SSc) patients. Methods: We reviewed the records of patients followed up in our centre over a period of 10 years. Those who have had at least one bone densitometry (DEXA) performed were included in the study. Demographic and basic clinical characteristics were recorded for all, including results of the DEXA scans and PPI treatment prior to DEXA (none, standard dose PPIs or high dose PPIs). Data on potential confounding factors, (smoking history, steroid, bisphosphonate treatment) were also collected. Ordinal logistic regression was used to assess the effects of these factors on the DEXA results. Results: 199 SSc patients were included in this study. Of those 91% were female, 31% had diffuse disease. Mean age at first DEXA scan was 57 years. Mean disease duration at first DEXA was 12.7 years. Bone density was normal in 21%, 40% had osteopenia and 39% had osteoporosis. By univariable analysis, there was no significant association between prior PPI treatment and DEXA scan results (p ¼ 0.205). Among those who had normal DEXA, 22% have not had treatment with PPIs, 49% have had standard dose and 29% have had high doses of PPIs. Among those with osteopenia, 12.5% had not been treated with PPIs, while 47.5% and 40% had received standard or high doses of PPIs respectively. Among subjects with osteoporosis, 27% had not had PPI treatment, while 41% and 32% have had standard and higher than standard doses of PPIs. We found no association between gender, disease subset or antibody specificity and bone density. Body mass index (BMI) was negatively associated with development of osteoporosis while age showed a strong positive association. Presence of calcinosis showed a borderline significant association with development of osteoporosis (p ¼ 0.096). Interestingly, there was a strong association between calcinosis and PPI among patients who had not received PPIs, calcinosis was present in 12.5%, among those on standard dose PPIs, 20% had calcinosis and among those on high doses of PPIs, calcinosis was present in 39%. Multivariable analysis of the effect of PPIs on bone density was fitted. After adjusting for age, BMI, steroid and bisphosphonate treatment, there was no association between PPI treatment and development of osteopenia or osteoporosis. Conclusion: There was a lack of association of prior PPI treatment and development of osteoporosis but our data indicate a potential association between calcinosis with prior PPI treatment and osteoporosis. The latter would warrant further study in a larger cohort. Our results suggest that evaluation of coexisting risk factors for osteoporosis is required for SSc patients on PPI. Disclosure statement: The authors have declared no conflicts of interest. Background: Renal involvement in systemic sclerosis (SSc) includes scleroderma renal crisis as well as progressive organ fibrosis. Detection and management of these disease complications is challenging and there is a clinical need for biomarkers that reflect renal involvement. The immunoglobulin superfamily adhesion molecules ICAM-1 and VCAM-1 are upregulated in affected tissues in SSc and other connective tissue diseases. Serum levels of ICAM-1 and VCAM-1 have been elevated in previous studies, but in some instances this reflects the multi-organ burden of disease and organspecific analysis may to be more robust. Methods: We collected urine and serum from 80 SSc patients, with or without renal disease, and compared them with patients with CKD of other causes (n ¼ 10) and healthy controls (n ¼ 12). We used beadbased multiplex analysis to measure cell adhesion molecule concentrations. Results were compared between groups by Kruskal-Wallis test.
URINARY CELL ADHESION MOLECULES AS MARKERS OF RENAL INVOLVEMENT IN SYSTEMIC SCLEROSIS
Results: 40 SSc patients had CKD defined by eGFR and urinalysis. Risk factors for renal involvement (SSc-CKD) included diffuse skin involvement and anti-RNA polymerase III antibodies. Serum concentrations of ICAM-1 or VCAM-1 did not differ significantly between SSc-CKD and the three control groups. Urine VCAM-1 concentrations were increased in SSc patients with renal involvement (mean VCAM-1:creatinine ratio 922, SD 953 versus 654, SD 708 for those without renal involvement) but this did not reach significance. Urine ICAM-1 was markedly upregulated in SSc-CKD (mean ICAM-1:creatinine ratio 1601, SD 1394 versus 806, SD 701 for SSc without renal involvement and 1307, SD 1211 for CKD of other causes, p < 0.001).
Conclusion: This is the first study to examine urinary cell adhesion molecule concentrations in SSc. Our results confirm the potential utility of urine soluble ICAM-1 as a marker of renal involvement in SSc. Together with previous work by our group on urinary chemokines, the finding of raised urine cell adhesion molecules in the absence of raised serum concentrations supports the utility of urine biomarkers in defining localized SSc disease activity. Disclosure statement: The authors have declared no conflicts of interest.
A MULTICENTRE RELIABILITY AND VALIDITY STUDY OF LASER SPECKLE CONTRAST IMAGING AND THERMOGRAPHY IN PATIENTS WITH RAYNAUD'S PHENOMENON SECONDARY TO SYSTEMIC SCLEROSIS
Background: Objective and reliable outcome measures for clinical trials of novel drugs to treat systemic sclerosis (SSc) related Raynaud's phenomenon (RP) are currently lacking. Laser speckle contrast imaging (LSCI) and thermography are two non-invasive measures of perfusion that show excellent potential but require further clinical assessment. The purpose of this multi-centre study was to determine the reliability and validity of a mild cold challenge protocol using both LSCI and thermography (including low-cost mobile phone thermography).
Methods: 159 patients with RP secondary to SSc were recruited from 6 UK specialist SSc centres. Patients underwent a cold challenge on 2 consecutive days; 158C water submersion of gloved hands for 1 minute, then un-gloved reperfusion and rewarming at 238C room temperature over 15 minutes. Baseline and changes in blood flow and temperature were imaged simultaneously using LSCI (relative perfusion) and thermography (skin temperature), respectively. Mobile phone thermography images were taken at baseline, 0 and 15 minutes post cold challenge. Parameters (Table 1) were calculated locally and data analysis performed centrally. Data were averaged across 8 digits to obtain a single measurement for each parameter for each technique at both visits. Test-retest reliability was assessed using intra-class correlation coefficients (ICC). Estimated latent correlations assessed the convergent validity of the LSCI and thermography (R version 3.2.3). Results: Median age was 63.3 years, SSc disease duration 9.6 years, 84% female, 77% limited cutaneous SSc. Both techniques had substantial reliability for area under the curve (AUC) ( Table 1) . Thermography reliability varied from moderate to strong and LSCI from moderate to substantial (Table 1) . We did not find either technique to be superior in this regard. Very high latent correlations of LSCI and thermography were present for AUC and MAX (Table 1) . Mobile phone thermography AUC reliability was found to be substantial. Conclusion: This is the first multi-centre study examining the reliability and validity of a cold challenge protocol using LSCI and thermography in patients with RP secondary to SSc. LSCI and thermography demonstrated moderate to strong reliability and therefore good potential as digital vasculopathy outcome measures. Furthermore, LSCI and thermography appear to have very high convergent validity. In this study, we explore the relationship of macrophage CD206 and P2X 7 expression to Rodnan Skin Score. The role of these cells in establishing fibrosis was also examined in vitro. Methods: 17 SSc patients and 9 controls were consented and their skin scores recorded. Macrophages were derived from peripheral blood mononuclear cells (PBMCs) and identified through CD14 expression by FACS. CD206 and P2X 7 co-expression was quantified. CD206 immunofluorescence of skin biopsies was also performed. Macrophages were co-cultured with 8 Â 10 4 and 2 Â 10 4 fibroblasts in a collagen matrix and within a monolayer respectively. Collagen gel contraction was quantified as a measure of fibrotic activity. CTGF and Collagen mRNA expression from gel matrices and cellular monolayers was quantified by qPCR. Blisters were created using established methods and blister fluid collected at 24 hours. Cellular infiltrates were analysed for CD14 and CD206/P2X 7 co-expression by FACS as with PBMCs. Results: CD206 and P2X 7 expression is higher on SSc PBMC-derived macrophages (mean fluorescence 776.1 SD ¼ 409.1, 724.4 SD ¼ 455.3) compared to healthy controls (mean fluorescence 632.2 SD ¼ 73.7, 472.9 SD ¼ 25.4). There is significant correlation of CD206 expression to P2X 7 expression (p < 0.001, r 2 ¼0.76) and CD206 expression is significantly correlated to Rodnan skin score (p < 0.05, r 2 ¼0.26). P2X 7 expression is positively correlated to skin score. Double positive P2X7 and CD206 cells were seen in a subgroup with higher skin scores. Fibroblasts co-cultured with macrophages showed increased CTGF and collagen mRNA by qPCR. CTGF mRNA was positively correlated with macrophage P2X7 (r 2 ¼0.23) and CD206 (r 2 ¼0.81) expression. Preliminary work suggests contraction of collagen discs in fibroblast and macrophage co-culture is increased with SSc macrophages compared to healthy controls. Conclusion: Data indicate a correlation between disease severity and CD206 expression by macrophages. Up-regulation of CTGF and Collagen expression in fibroblasts co-cultured with CD206 high macrophages suggests a role for these cells in pathogenic fibrosis. The coexpression of high levels of P2X7 with CD206 also indicates a possible role for the purinergic pathway in SSc fibrosis. Future work will examine the mechanism of macrophage-fibroblast cross-talk and investigate the effect of purinergic pathway inhibitors. Background: A 43 year old woman with a background of systemic lupus erythematosus (SLE) and secondary Sjö gren's syndrome, developed an acute hydroxychloroquine (HCQ) retinopathy following treatment with HCQ 200mg BD for 9 years. This resulted in significant impairment of visual acuity. She had regular optician review while taking HCQ. Methods: This case has led us to scrutinize the variability of routine referral for ophthalmology assessment in HCQ patients in our Trust, beyond baseline optician tests and recommendation for annual optician review. Hydroxychloroquine is known to cause retinopathy; initial changes are reversible, but not once visual impairment has occurred. Results: The Royal College of Ophthalmologists (RCO) published guidance in 2009 that did not recommend routine ophthalmology screening, due to the rarity of retinopathy and lack of a reliable test, at the time, to detect it at a reversible stage. The incidence of HCQ-related retinal toxicity may be more common than previously thought, possibly exceeding 1% after 5-7 years of use. This rises towards 2% between 10 and 15 years of continuous usage. In addition, the emergence of more sensitive diagnostic techniques such as Fundus Auto Fluorescence (FAF) have suggested that retinal changes may be detected at an earlier stage, potentially avoiding late progression of retinal toxicity and visual loss. In light of these developments, the American Academy of Ophthalmology updated recommendations to include baseline examination before treatment and annual testing by an ophthalmologist after 5 years of therapy. Current evidence suggests that retinopathy is very unlikely to occur until the total cumulative dose is beyond 1000g (7 years of 400mg per day). Therefore dose reduction to 200mg daily, where possible, may reduce risk of retinopathy development. Conclusion: We propose that in order to detect retinopathy at an early stage, prior to visual impairment, all patients treated with HCQ are referred to ophthalmology specialists for screening no later than 5 years after starting therapy. We suggest that the current RCO recommendations remain unchanged for the first 5 years of treatment, as baseline retinopathy testing, prior to initiation of HCQ, is unlikely to be logistically feasible. This might otherwise cause unacceptable treatment delay for patients with autoimmune rheumatic diseases, therefore a pragmatic balance must be struck. Furthermore, in order to reduce the chance of HCQ retinopathy, clinicians should aim to reduce dose in patients with well controlled rheumatic disease. Disclosure statement: The authors have declared no conflicts of interest. Background: Pain is a major determinant of poor quality of life in primary Sjö gren's syndrome (PSS) and a priority symptom for United Kingdom Primary Sjö gren's Syndrome Registry (UKPSSR) patients. Although neuropathic and chronic pain phenotypes have previously been identified, little is really known about this symptom in PSS. In order to further explore the concept of pain in PSS further, focus groups were conducted with patients and their family members.
MACROPHAGES FROM A SCLERODERMA SUBGROUP WITH HIGHER SKIN SCORES EXPRESS ACTIVATION MARKERS AND INDUCE FIBROBLASTS IN CO-CULTURE
IT ISN'T PAIN PURE AND SIMPLE: EXPERIENCES OF
Methods: 10 UKPSSR patients in the north-east of England and 3 spouses of patients took part in 3 focus groups to explore their experiences of pain and other symptoms. They were asked to describe their pain and how they/their spouse managed it. Focus groups were audio-recorded and transcribed verbatim. Transcripts were analyzed using thematic analysis. Results: Although pain is a feature of PSS, it was not experienced by all patient participants. For those who experienced pain, the levels varied and it was not present every day. The word pain was not always regarded as an appropriate description of the experience and it should be used interchangeably with the word discomfort. Pain and discomfort were regarded on a scale, from mild irritation through to excruciating pain. Pain and discomfort often followed a fatigue episode or excessive activity. Different experiences of pain and discomfort included; articular pain, aching muscles, headaches, peripheral paresthesia, noise intolerance, bowel discomfort, nausea, eye discomfort, cramp-like pain in the parotid glands and pain/ discomfort relating to ill-fitting dentures and dental treatments. These experiences sometimes prevented engagement in social/leisure activities and could contribute to social isolation. Patients believed that when others -including family and clinicians -demonstrate little understanding of these symptoms, it had a negative impact on their mood. Self-management strategies used by patients included regularly setting an achievable and enjoyable goal, use of TENs devices, and accessing alternative therapies e.g. Shiatsu and acupuncture. Conclusion: Pain/discomfort in PSS is a heterogeneous concept. An empathic approach from the clinician towards patients' pain/ discomfort may avoid further emotional distress for the patient. Experiences of pain and discomfort in PSS are unique and should be explored with the patient prior to planning appropriate targeted interventions. Methods: We present a case of organizing pneumonia (OP) where the diagnosis of primary Sjogren's syndrome followed the presentation of a young male with suspected Cryptogenic Organizing Pneumonia.
Results: 27 year old gentleman with no significant past medical history. He initially presented with symptoms of chronic cough and pleuritic chest pain for 6 months. He was treated for community acquired pneumonia without resolution of bilateral apical opacities on chest radiograph. HRCT of thorax demonstrated apical consolidative changes with scattered inflammatory nodules. Ultrasound guided biopsy of parenchymal lung opacity showed evidence of OP with no associated conditions on detailed immunological work up. He was commenced on oral corticosteroids for COP leading to a remarkable initial improvement before subsequently deteriorating and presenting with bilateral painful swelling of the salivary and mandibular glands, significant dryness in his mouth, myalgia, generalized joint pain and considerable weight loss. Initial ultrasonic assessment of the parotid glands revealed abnormal non-specific features and subsequent biopsy was consistent with histological features of PSS. IgG subclass and IgG4 staining of parotid biopsy ruled out IgG4 disease (Table 1) . Investigations for lymphoma and infective causes were negative. His symptoms settled down with 3g of IV methylprednisolone over 3 days. He was subsequently started on azathioprine and oral prednisolone. This patient is currently under the joint care of rheumatology and respiratory physicians in order to optimize his management and closely monitor for disease complications.
310 þ T helper (Th) cells play a crucial role in the pathogenesis of primary Sjö gren's syndrome (pSS). Previous studies identified a predominance of Th1 phenotype, in particular in pSS patients with increased histological scores and presence of serum autoantibodies. We aimed to identify the peripheral T-cell phenotype abnormalities in patients with pSS compared to secondary SS associated with systemic lupus erythematosus (SS/SLE) and SLE alone, and correlate them with clinical and serological parameters, and lipid raft expression as marker of T cell activation. Our hypothesis is that disturbance in the functional properties of peripheral blood T cells can contribute to the immunopathogenesis of SS, and could have therapeutic potential. Methods: Blood samples and clinical and laboratory parameters from 32 patients with pSS, SLE and SS/SLE and 13 age/sex matched HC were obtained. We used flow-cytometry to perform T-cell immunophenotyping and analysis of lipid-raft expression. Results: Comparisons between different T cell population expressions (NS -no significant difference) are summarized in Table 1 . 312 
NS
Total lipid raft expression in CD4 þ T cells correlated positively with the disease activity score in pSS (ESSDAI) (p ¼ 0.0305, r ¼ 0.4617), while the global BILAG score correlated positively with CD4 þ CD25 À CD127 þ T responder in SLE patients (p ¼ 0.0235, r ¼ 0.7026). NS, no significant difference.
Conclusion:
Patients with pSS, SS/SLE and SLE have different T-cell phenotypes. The most significant T cell abnormalities were found in patients with SLE, however a significant correlation between lipid raft expression as marker of cell activation and disease activity score was found only in pSS patients. This is particularly relevant for therapeutic purposes, as CTLA-4 blockade is mediated by lipid rafts, and could provide in further larger study the possibility to identify which pSS patients are most likely to respond to abatacept. Disclosure statement: The authors have declared no conflicts of interest.
SYSTEMIC LUPUS ERYTHEMATOSUS AND ANTI-PHOSPHOLIPID SYNDROME
ALVEOLAR HEMORRHAGE WITH RECURRENT PNEUMOTHORACES AS FIRST PRESENTATION OF SYSTEMIC LUPUS ERYTHEMATOSUS
Nabeel Abdulla, Housam Sarakbi and Abdul-Wahab Al-Allaf Rheumatology, Hamad General Hospital/Hamad Medical Corporation, Doha, QATAR Background: Recurrent pneumothorax is rarely reported manifestation of SLE. Methods: We report a 24-year-old lady who presented with diffuse alveolar hemorrhage and then developed recurrent Pneumothoraces with bronchopleural fistula as the first presenting manifestation of SLE. Results: We describe a 24 year old lady who presented to A&E with fever and hemoptysis for 2 days. A week prior to presentation she developed dry cough, right sided pleuritic chest pain and later on hemoptysis. In the A&E her condition rapidly deteriorated and she was intubated and admitted to ICU. Chest X-ray and CT chest showed extensive patchy alveolar opacities in both lungs associated with consolidation. Bronchoscopy confirmed alveolar hemorrhage. The family gave a history of photosensitivity, skin rash, hair fall, arthralgia and Raynaud's in the preceding 4 weeks. Possibility of a connective tissue disease was raised. Investigations revealed autoimmune hemolytic anemia, mild leucocytosis. Both C3 and C4 were low, with positive ANA (>1/1280), Anti-ds DNA (70 IU), Anti Smith and Anti RNP, with negative antiphospholipid antibodies. Viral panel screening revealed Epstein-Barr virus (200 IU/ml) with negative Cytomegalovirus and Adenovirus. Urine analysis was normal. Diagnosis of SLE causing diffuse alveolar hemorrhage was made. She was treated with 250mg IV pulses methylprednisolone for 3 days and Plasma exchange. Then 1gm of IV Rituximab was given. The patient also developed thrombotic microangiopathy with high schistocytes on peripheral smear, profound thrombocytopenia and normal coagulation profile. With continuing plasma exchange the cytopenias recovered. On Day 6 she developed Right sided pneumothorax, in spite that the ventilation was of standard protocol. Chest tube was inserted but it did not resolve in spite of suctioning and change of position. She also developed extensive surgical emphysema. Repeating chest CT showed new cavitating lesion measuring 3.2cm at right middle lobe. On Day 24 she developed another large right pneumothorax with mediastinal shift, 3 days after she was extubated and removal of chest drain. Accordingly, the patient was intubated again and 2 chest tubes inserted. The she had another attack of alveolar hemorrhage which has been confirmed by bronchoscopy. Plasma exchange and IV pulse of 500mg Methylprednisolone were given for 3 days. Bronchoscopic lavage confirmed CMV infection, so ganciclovir was started. As she deteriorated another Bronchoscopy revealed bronchopleural fistula, accordingly right sided endobronchial blocker was inserted. On Day 67 patient's respiratory condition again deteriorates and this confirmed to be due to a left apical pneumothorax. Again chest tube was inserted. Two weeks later she succumbed due to overwhelming sepsis. Conclusion: Recurrent pneumothorax is unusual presenting symptoms of SLE and it carries bad prognosis. High skilled and early cardiothoracic intervention in specialized unit is recommended for such complicated cases. Disclosure statement: The authors have declared no conflicts of interest.
ABSTRACT WITHDRAWN
PREDICTORS OF FRACTURES IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
Mrinalini Dey, Richa Sinha and Marwan Bukhari Rheumatology, University Hospitals of Morecambe Bay NHS Foundation Trust, Lancaster, UNITED KINGDOM Background: The aetiology of bone loss in systemic lupus erythematosus (SLE) is multifactorial, influenced by many factors in addition to changes in body composition. Studies have found that long-term corticosteroids (CS), previous osteoporotic fractures and increasing age, decrease bone mineral density (BMD). The effect of factors such as body mass index (BMI) and fat mass are less well-characterized. We set out to determine the fracture risk in a population of patients referred for dual-energy X-ray absorptiometry (DXA) scanning. Methods: Patients referred for DXA in a district general hospital, between 2004 and 2014, were recruited to the study. In addition to femoral and vertebral BMD, height, weight and BMI, the following were recorded: age, rheumatoid arthritis, smoking, alcohol, family history of fractures, history of secondary osteoporosis, corticosteroid use, total average proportion of fat, average tissue thickness, fat mass and lean mass. Data were analysed using chi squared test for categorical data, and T test for continuous data. Logistic regression was used to model fracture risk. Results: 150 patients (141 female), with a diagnosis of SLE were included. 52 (34.6%) had sustained at least one fracture. Older age was associated with increased fracture risk, as well as increased BMI, weight, fat mass, and average tissue thickness, and decreased lean mass (Table 1) ; these results remained unchanged when adjusted for steroid use. Total femoral and vertebral BMD were increased in those who had not sustained a fracture. History of smoking and rheumatoid arthritis significantly increased the risk of fractures. Conclusion: Our study suggests that SLE patients with increased age, BMI and fat mass, and a history of smoking and/or rheumatoid arthritis, are at increased risk of fractures. To our knowledge, this is the first such study demonstrating a correlation between increased fat mass, adjusted for steroid use, and fracture risk, in adults. The association with increased fat may indicate a differential effect of fat on bone metabolism and a different effect of lessening of lean body mass. 315 Cytokine expression in serum is often at low levels and therefore traditional ELISA methods have inadequate sensitivity. Custom high sensitivity multiplex arrays offer the opportunity to measure multiple cytokines within a single serum sample. We aimed to investigate the association between cytokine expression and disease activity in patients with established SLE using high sensitivity multiplex ELISA. Methods: Female healthy subjects and patients with SLE (!4 ACR criteria) were recruited between 2007 and 2013 from Central Manchester NHS Foundation Trust. Disease activity was measured using the SLEDAI-2K and BILAG-2004 indices. Active disease was defined as presence of any of: SLEDAI score >4, 1 BILAG A score, or 2 BILAG B scores. The expression of 10 cytokines (IFNa, Blys, IL-10, Il-17, IL-18, IL-21, CXCL10, CXCL13, MCP-1 and pentraxin-3) was measured in serum by high sensitivity bead-based Multiplex ELISA. Principle component analysis (PCA) of the 10 cytokines followed by Kmeans clustering was used to identify patient groups according to cytokine expression. Results: We recruited 13 healthy control (HC) subjects and 96 SLE patients with median (IQR) age of 40 (32, 49) and 51 (44, 59) years respectively. The SLE group was 77% (74/96) Caucasian with a median disease duration of 11.7 (6.8, 21.4) years. The median dose of steroids was significantly higher among patients with active disease [12.5 (7.5, 17.5) vs. 0 (0, 5)mg/day, p < 0.001] but there were no differences in antimalarial or immunosuppressant use. Compared to HCs, SLE patients had significantly increased levels of CXCL10 and CXCL13. Patients with active SLE had significantly increased levels of BLys, IL-18, CXCL10, IL-17 and pentraxin-3 compared to inactive patients. Cluster analysis revealed 3 groups [CXCL13/IL18/CXCL10 high (n ¼ 10); IL21/Blys/IL10/IFNa/IL18/IL17 high (n ¼ 6); all cytokines low (n ¼ 93)]. Both group 1 and 2 had high disease activity with 7/10 (70%) and 4/6 (67%) active patients compared to group 3 (11/80, 14%). All HCs were clustered into group 3. Patients in group 1 were more likely to have inflammatory arthritis as part of their disease and had lower C3 and C4 complement compared to group 2. Multinomial logistic regression models identified that group membership was associated with clinical subgroup (HC/inactive SLE/active SLE) and steroid use, but not age, ethnicity or disease duration. Conclusion: Cytokine profiles are variable in active SLE but at least 2 distinct subgroups are apparent. Patients with inactive SLE have similar profiles to healthy controls. Our findings suggest multiplex ELISA can identify distinct immunophenotypes among SLE patients which may lead to a more targeted approach to treatment. Disclosure statement: The authors have declared no conflicts of interest. Background: In patients with SLE who had previous adverse obstetric outcome(s) the risk of an adverse outcome in subsequent pregnancy rises. The primary objective of this study was to assess the impact of a protocol based multidisciplinary care on pregnancy outcome(s) in a prospective cohort of patients with SLE who had previous adverse obstetric outcome(s). Methods: Between March 2010 and March 2016 all patients with SLE with previous at least one adverse obstetric (either maternal or foetal) outcome desirous of having more children were prospectively enrolled. All patients had in-depth preconception counselling and were prospectively followed throughout the pregnancy as per the protocol with multidisciplinary team input. Briefly the protocol comprised of pre natal counselling, pre and post natal drug and disease status review, risk stratification, periodic ante-natal visits for the monitoring of pregnancy (including with obstetric ultrasounds) and disease, 2D echocardiogram at weeks 18 and 32 if Ro/La were positive and post natal contraception advice. Therapeutic changes were made as necessary at each visit. Results: Fifty-three patients (age meanAESD years; 28AE3) were enrolled. Previous poor obstetric outcomes were: miscarriage(s) in 30, MTP in 9, preterm labour with IUGR in 9, intrauterine death, still birth in 2 each and pre ecalapmsia in 1. Nine patients had secondary APS and 14 had both or either Ro/La positive. Nine had lupus nephritis (LN); more than 6months ago in all. There were 44 (85%) live births (10 LBW; instrumentation or caesarean section in 28). Eight patients had miscarriages. One decided against becoming pregnant after the initial counselling. Sixteen patients (30%) had lupus flare (9 mild, 5 moderate and 2 severe based on SLEPDAI). Conclusion: Majority of patients in our prospective cohort had acceptable pregnancy outcome. This highlights the need to provide integrated, innovative solution to the complex need of SLE pregnancies in developing countries such as India. Background: Cognitive dysfunction, especially problems with attention, is common in systemic lupus erythematosus (SLE). The causes of cognitive dysfunction in SLE may be numerous from the more obvious such as cerebral infarcts to the more subtle such as mood disorders. As such trying to determine the effect disease activity in SLE has on cognitive function is a difficult task. This study aims to examine the differences in attention between SLE patients with active disease (SLE-F) and those with stable disease (SLE-S). Methods: 20 SLE-F and 36 SLE-S participants were assessed for differences in attention using a behavioural measure, the CANTAB rapid visual information processing task (RVP). 16 SLE-F and 23 SLE-S participants also had an fMRI scan, during which they completed a cognitive task (n-back) that included an attentional component. The differences in blood-oxygen-level dependent (BOLD) signal response to the n-back task were recorded. Demographic, clinical and psychiatric measures were also recorded. Analysis was undertaken using SPM 12 for the scanner task and SPSS 22 for all other measures. Results: All SLE patients met ACR or SLICC criteria for SLE. Characteristically the two groups were well-matched (Table 1) . The only differences were in disease activity measures and percentage of patients on any immunosuppressant medication. For both these measures it was expected that the SLE-F group should score higher. The RVP task results showed no difference in performance on the attention task (p¼0.148), however, there were differences from the fMRI task. The SLE-F group had increased BOLD responses to attention in both the left middle cingulate gyrus (p¼0.011) and supplementary motor cortex (p¼0.044) compared to the SLE-S group. Conclusion: Both SLE groups performed equally well on the behavioural attention task suggesting there are no effects of disease activity on attention performance. However, the fMRI results showed that the SLE-F had greater BOLD responses in regions involved in cognitive processing. This difference could be attributed to disease activity given that the groups were well-matched on key characteristics. Ultimately, the SLE-F groups may have to employ compensatory brain mechanisms to maintain the same level of performance as the SLE-S group on cognitive tasks. Background: Type I interferons have been implicated in the pathogenesis of systemic lupus erythematosus (SLE), but much less is known about their role in other connective tissue diseases (CTDs). We aimed to determine the prevalence of a whole-blood type I interferon signature across CTDs, and to identify clinical and serological factors associated with elevated interferon pathway activity. Methods: Subjects were recruited from Central Manchester University Hospitals, UK between May 2014 and March 2016. Patients were categorized by their physician diagnosis into SLE, undifferentiated CTD (UCTD), mixed CTD (MCTD), Sjogren's syndrome (SS) and systemic sclerosis (SSc). Autoantibodies (ds-DNA, Ro, La, Smith, U1RNP, CCP, chromatin, centromere, Jo-1 and Scl-70) were measured using multiplex ELISA. RT-qPCR was performed on cDNA derived from whole blood and the median fold change of six interferonsimulated genes (IFI27, IFI44L, IFIT1, ISG15, RSAD2, SIGLEC1) was compared with the median of healthy controls, to create an interferon sensitive gene (ISG) score for each patient. Scores higher than the mean of the controls plus two standard deviations (>2.466) were designated as a positive score. Results: We recruited 95 subjects with a median (IQR) age of 48.3 (32.9, 57.4) years. 88 (92.6%) were female, 72/94 (77%) were Caucasian and the median disease duration was 7.68 (3.06, 14.81) years. The most commonly present autoantibodies were anti-U1RNP (26.3%), anti-Ro/SSA (25.2%) and anti-dsDNA (24.2%). In total, 60/95 (63%) subjects had at least 1 positive autoantibody from the above list. Across all subjects, 33/95 (34.7%) had a positive ISG score. The median ISG scores was higher in patients with Sjogren's syndrome or MCTD, compared to healthy controls (Kruskal-Wallis, p ¼ 0.005 across all groups). All 3 SSc patients had a negative ISG score. In univariate logistic regression models (excluding anti-centromere and anti-Jo1 due to low numbers), a positive ISG was significantly associated with the presence of ds-DNA, Smith, Ro, RNP and 319. At least one of the antiphospholipid antibodies was present in 41.8% of the patients, with thromboembolic manifestations and/or recurrent fetal loss present in 18.3% of the patients. Neuropsychiatric manifestations were evident only in 7.8% of the patients, with seizures being the most common neuropsychiatric manifestation, present in 4% of the patients. 33.1% of the patients had nephritis, which succeeded the onset of the disease by a mean duration of 20 AE 21.3 months. 29.3% continued follow up and received induction therapy according to the guidelines at the time of presentation. Of which, 24.9% continued follow up, and showed partial (9.9%) and complete (15%) response. However, 3.6% of the patients developed a second renal flare, which presented after induction for first renal flare by a mean of 20.2 AE 21.31 months. There were gender differences in the disease characteristics. Cutaneous vasculitis, nephritis, and hypocomplementemia were statistically higher in males (p ¼ 0.02, p ¼ 0.01, and p ¼ 0.002 respectively). Whereas, synovitis, and alopecia were statistically higher in females (p ¼ 0.012 and p ¼ 0.005 respectively). Conclusion: Synovitis and malar rash were the most common manifestations in our study. Secondary antiphospholipid syndrome was present in 18.3% of the patients. Whereas nephritis was present in 33.1% of the patients. Disclosure statement: The authors have declared no conflicts of interest.
IMPROVED OUTCOMES IN HIGH-RISK LUPUS PREGNANCIES: USEFULNESS OF
ANTI-RITUXIMAB ANTIBODIES CONTRIBUTE TO THE LACK OF RESPONSE TO RITUXIMAB THERAPY IN SOME SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS
Madhvi Menon, Edward Smith, Elizabeth Jury and Claudia Mauri Medicine, University College London, London, UNITED KINGDOM Background: As B cells are central to the pathogenesis of SLE, B cell depletion therapy (rituximab therapy) is often used to treat SLE patients. Although rituximab has been effective in improving clinical response in many SLE patients, not all patients respond to rituximab therapy. A recent study reports that six months after the first rituximab treatment, 40% patients showed a complete response, 27% a partial response whereas the remaining 33% did not respond. A major limitation of biological therapies is the development of anti-drug responses in some patients, in particular the production of anti-drug antibodies (ADA) that significantly reduce drug efficacy. Currently, there is no report of ADAs to rituximab therapy. Methods: We assessed the expression of ADA to rituximab in 77 patients with SLE treated with rituximab. 25 of these patients were followed longitudinally for up to 6 years after initial rituximab therapy. Development of ADA to rituximab was correlated with the British Isles Lupus Activity Group (BILAG), a clinical measure of disease activity. Results: We report the existence of anti-rituximab antibodies in patients with SLE that is associated with clinical response. 46 out of 77 rituximab-treated SLE patients tested positive for anti-rituximab antibodies (titre range from <2 to 1,080,000). Furthermore, longitudinal analysis of 25 patients before and after treatment with rituximab revealed that anti-rituximab antibodies were associated with failure to respond to therapy in some patients, particularly those with high titres of anti-rituximab antibodies. Our current focus is to understand the mechanisms that drive immunogenicity in SLE patients as a way to improve administration of rituximab, and to reduce the number of patients that fail to respond to rituximab. To achieve this, we are using a novel immunophenotyping platform to screen 332 markers on B cells to identify an immune-signature associated with anti-rituximab antibodies. Conclusion: Monitoring anti-rituximab ADA and its associated immune signature may predict response to rituximab in SLE patients. 
REGULATORY B CELLS IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
Madhvi Menon, Edward Smith, Elizabeth Jury and Claudia Mauri Medicine, University College London, London, UNITED KINGDOM Background: Systemic lupus erythematosus (SLE) is a highly heterogeneous autoimmune disease characterized by multiple immunological abnormalities that contribute to its complex etiology. B cells are considered central to the pathogenesis of SLE, contributing to the disease by both antibody-dependent and antibody-independent mechanisms. In addition to defects in effector B cell function, IL-10-producing CD19
hi regulatory B cells (Bregs), which are important contributors to the maintenance of tolerance, have been reported to be defective in SLE patients. While the impaired suppressive function of Bregs is partially due to reduced IL-10 production, several other defective mechanisms remain unknown. Here we propose phenotypic screening of 332 cell-surface markers using high throughput flow cytometry to compare the surface profile of CD19
hi B cells (Breg precursors), from healthy individuals and SLE patients for improved characterisation of Bregs. Methods: Using LEGENDScreen technology, a novel immune-phenotyping platform optimized in our laboratory, we measured the expression of 332 surface markers on CD19 þ CD24 þ CD38 hi B cells from 10 healthy individuals and 10 SLE patients. The antigen-specific fluorescence intensity for each subset was examined. Results: We have generated an immune-signature of SLE CD19
hi B cells that identifies 50 phenotypic markers differentially expressed in SLE patients compared to healthy individuals. Upon examining the functional characteristics of these different markers, two CD antigens were found to be involved with regulatory functions: CD39 and CD73. CD39 and CD73 are ectonucleotidases that hydrolyze exogenous ATP to adenosine 5 0 -monophosphate (5 0 -AMP) and adenosine; circulating CD39 hi B cell populations in healthy controls and SLE patients revealed that although the frequency was comparable, the mean fluorescence intensity of both CD39 and CD73 were significantly reduced in SLE patients (p < 0.05). Furthermore, after CD40L stimulation for 72 hours, the expression of CD39 and CD73 were further reduced in CD24 hi CD38 hi B cells from SLE patients compared to healthy individuals.
Conclusion: Thus, we have generated an immune signature of CD19
hi B cells in SLE. Our results suggest that in addition to IL-10 production, CD24 hi CD38
hi Bregs from healthy individuals may suppress immune responses via the dephosphorylation of adenine nucleotides to adenosine, and that this mechanism maybe defective in SLE patients. Disclosure statement: The authors have declared no conflicts of interest.
LUPUS AND AVASCULAR NECROSIS OF THE BONE: HAS THE INCIDENCE IMPROVED?
Alexis N. Jones, Beatriz Tejera Segura and David Isenberg Rheumatology Department, University College London Hospital, London, UNITED KINGDOM Background: With improvements in our management of lupus, the recognition of the long term harmful effects of steroids and the subsequent decline in their use, we postulated that there would be a reduction in the incidence of avascular necrosis of the bone (AVN) in these patients. Avascular necrosis of the bone is a well recognized complication of lupus with a reported prevalence of 4-9%. Corticosteroid use is considered to be the principal risk factor; although some cases of AVN occur in relatively steroid naïve patients. We reviewed the incidence of AVN in our cohort of lupus patients under long term follow up from 1978 to 2015. Methods: We performed a retrospective case control study of a large cohort (n ¼ 673) of patients diagnosed with lupus at University College London Hospital. Demographic data regarding age, sex, ethnicity, age of SLE diagnosis, age of AVN diagnosis, sites of AVN, steroid use, smoking and alcohol history and presence of antiphospholipid antibodies were retrieved from paper and electronic records Results: In our cohort, 21 (3.12%) patients were diagnosed with AVN (18F 3M). The mean age of onset of SLE was 26.5 (range 15-53 years). The mean age of diagnosis of AVN was 34.3 years (range 20-59). The femoral head was the most commonly affected site (75%) followed by ankle (10%), shoulder (5%), knee (5%) and lumbar spine (5%). 14 patients were on steroids at the time of presentation. 4 patients were not on steroids and 3 patients did not have clear documentation of steroid use. In the past 10 years, the incidence of AVN in our lupus cohort has increased with 0.7 new cases per year compared with 0.5 cases per year from 1978 to 2006 despite a reduction in the mean cumulative dose of steroids from 21.4g (1978-2006) to 11.5g (2006-2016) . Conclusion: Interestingly, in spite of a greater awareness about the dangers of steroids and reduction in their use, the incidence of AVN has increased slightly over the last 10 years. This finding prompts further work into the association between lupus and bone metabolism. Disclosure statement: The authors have declared no conflicts of interest. Background: Pregnancy in systemic lupus erythematosus (SLE) patients usually poses a great management challenge as it is associated with higher adverse pregnancy outcomes. The objectives of this study were to determine the prevalence and the associated factors of adverse pregnancy outcomes (APOs) in women with SLE. Methods: Medical records of SLE patients who had a complete prepregnancy, antenatal and delivery care in Putrajaya Hospital and Universiti Kebangsaan Malaysia Medical Centre (UKMMC) were reviewed. Adverse pregnancy outcomes (APOs) were defined as: Foetal loss (at any trimester) or neonatal death, Prematurity (birth before 36 weeks), Preeclampsia/Impending Eclampsia/ Eclampsia, and Intrauterine growth restriction (IUGR)/small-for-gestational-age (SGA) neonate (birthweight below the fifth percentile). Disease activity in pre-pregnancy and pregnancy was assessed using the British Isles Lupus Assessment Group's pregnancy index (BILAG 2004-P Index) .
PREGNANCY OUTCOMES AMONG MALAYSIAN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
Results: A total of 95 SLE patients with 148 pregnancies were reviewed. Six pregnancies were excluded from the analysis as they were medically terminated. Majority of the patients were Malay (n ¼ 66, 69.5%), followed by Chinese (n ¼ 24, 25.3%) and Indian (n ¼ 5, 5.3%). Systemic involvement was mainly musculoskeletal (74.7%), mucocutaneous (69.5%), haematological (54.7%), and lupus nephritis (45.7%). The prevalence of APOs was 60.6% and prematurity was the highest foetal complication (29.6%), followed by IUGR/SGA (27.5%). The prevalence of pre-eclampsia/impending eclampsia/ eclampsia was 22.5% while the rate of foetal loss was 19.6%. Univariate and multivariate analyses revealed that the independent factors associated with APOs were Lupus Anticoagulant (LA) positivity, pre-pregnancy active disease and persistent low complements C3/C4 and/or positive anti-dsDNA despite clinical remission in pre-pregnancy or antenatal period. Conclusion: The prevalence of APOs among Malaysian SLE patients was high and a tight disease control during pre-pregnancy and antenatal period is important as it is associated with lower adverse pregnancy outcomes. The induction regimen was 1gm doses of rituximab, 2 weeks apart except for 1 patient who had 375mg/m 2 weekly for 4 weeks; oral immunosuppression was discontinued prior to rituximab treatment. Further infusions were instituted at clinical signs of relapse, except for 3 patients who had 6 monthly maintenance doses for 2 years for severe orbital disease. Data regarding clinical characteristics, outcomes and safety of repeated cycles of rituximab were evaluated. Results: 10 patients (50% males) were assessed. Median Age was 60 years (range 42-71). Median disease duration was 10 years (range 2-28) and median follow up duration from first rituximab cycle was 5 years (range 1-10). All patients were ANCA positive (9 anti-PR3, 1 anti-MPO). Median treatment cycles were 3 (range 2-8), with mean cumulative dose of Rituximab of 5.5 grams (range 3-11). All patients had a good response to induction therapy with median pre-treatment BVAS of 14 (range 8-21), and median post treatment BVAS of 4 (range 1-8) and 1.5 (range 0-4) at 1 and 3 months respectively. The median duration to receiving first re-treatment was 11 months (range 6-72). Median time to further flare and requiring 2nd retreatment was 18 months (range 6-40). Response to treatment corresponded with decrease in ANCA levels in 6 patients while the rest were ANCA negative at 1-3 months after first infusion. All patients depleted B cells at 3-6 months post Rituximab. Increase in ANCA levels were detectable in 4 patients prior to clinical relapse and only 3 patients had B cell repopulation prior to relapse. No infusion related adverse events were recorded. 6 patients had low Immunoglobulin levels (either IgG, IgM or both) at 3-6 months after first cycle, and all 10 patients developed hypogammaglobinaemia after repeated cycles. 2 patients had urinary tract infections. 1 patient developed recurrent infections with persistent hypogammaglobinaemia after induction therapy and required long-term monthly replacement intravenous Immunoglobulin. She successfully received further Rituximab for a relapse. Conclusion: Rituximab re-treatment on demand at clinical relapse may be an effective and well tolerated treatment option in patients with refractory/relapsing GPA.
Disclosure statement: D.P.D'C.: Consultancies: AstraZenaca, Eli Lilly, GlaxoSmithKline, Roche.P.S., A.C., P.M.K.L and S.S. have declared no conflicts of interest. BVAS score was recorded in 10/130 (8%) at diagnosis and 8/121 (7%) at 6 months. Remission Induction: Cyclophosphamide (CYC) was used in 99 (76%), Rituximab in 6 (5%), and other agents in 25 (19%). Remission at 6 months was achieved in 83% of patients. Mortality: 1-year survival was 91.5%, similar to other studies. Among the 130 patients receiving Cyclophosphamide for new diagnosis or relapse:
COMPLIANCE WITH STANDARDS OF CARE FOR ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODYASSOCIATED VASCULITIS IN THE MIDLANDS AND EAST OF ENGLAND
The correct dose of cyclophosphamide (based on BSR recommendations for age, weight and renal function, within a tolerance of _100mg) was administered in only 58%, with under-dosing in 34% and over-dosing in 8%; at least one FBC was checked 7-10 days after the first dose of cyclophosphamide in 92% patients; the total cumulative dose per patient was median 6 g, interquartile range 4-9 g, range 0.1-21 g. No patients exceeded a lifetime exposure of 25 g; Mesna was given in 76% of patients. PJP prophylaxis was given in 82% of patients; 25% patients had an infection requiring hospital admission during or within 6 months of completing their cyclophosphamide therapy.
Among the 76 patients who received Rituximab:
Among the 16 patients treated with Rituximab for a new diagnosis, 15 (94%) received 1 g_2, and 1 (6%) received 375 mg/m2_4. Among the 60 patients treated with Rituximab for relapse, 35 (58%) received 1 g_2, and 16 (27%) received 375 mg/m2_4, 7 (12%) received 1 g_1 and it was not specified in 2 (3%). 97% patients met NHSE or NICE criteria for Rituximab eligibility. PJP prophylaxis was given in 65% of patients. Immunoglobulins were checked prior to Rituximab in 93% patients.
Conclusion: This audit cohort had similar remission and mortality rates to published studies. However, rates of serious infection associated with cyclophosphamide were much higher than in the selected populations in (EUVAS) clinical trials. There is a need to improve compliance with patient-safety standards related to the administration of non-cancer chemotherapy, particularly the dosing of cyclophosphamide. Development of a national treatment protocol/ checklist to reduce this heterogeneity of care should be considered as a priority. Results: 18 patients (45% women) were identified; mean age was 59 (Range 21-82 years). Most were Caucasians (83%) and the rest were Afro-Caribbean. Median follow up was 16 months (1 month-10 years). The clinical subgroups were idiopathic aortitis (8), Giant cell arteritis (4), Takayasu's arteritis (3), Granulomatosis with Polyangiitis (1), isolated thoracic aortitis (1) and retroperitoneal fibrosis (1). There was a diagnostic delay of 0-24 months (median 2m) from initial onset of symptoms to diagnosis, two patients were diagnosed incidentally on imaging. At initial presentation, the median CRP was 50 (5-255) and the median ESR was 56 (range 5-106). ANCA positivity was observed in 3 patients, negative in 14 and ANCA was not measured in 1 patient. Mean creatinine at presentation was 76 umol/L. Histology reports were available for 5 patients (28%) which showed IgG4 positive plasma cells in 1 case (aortic tissue), granulomatous changes on subglottic tissue in 1 patient with known GPA, 1 positive and 2 negative temporal artery biopsies. FDG-PET scans in 16 patients (89%) showed pan-aortitis in 5 patients, thoracic and subclavien artery uptake in 4, ascending aorta and arch involvement in 3 patients, infrarenal aortitis in 1 and 2 had negative FDG-PET scans. Mean initial treatment dose Prednisolone dose was 30mg (7.5-80); 9 patients received DMARD therapy (6 on Methotrexate, 3 on Azathioprine), while 2 had cyclophosphamide, 1 had rituximab and 1 had FEC-T chemotherapy for associated Lymphoma. Significant disease related complications included 2 patients needing thoracic stents and aortic root repair, 1 each with abdominal and thoracic artery dissection and one developed cardiac amyloidosis. 3 deaths were reported: 1 due to treatment noncompliance and 2 unrelated deaths. Conclusion: Inflammatory Aortitis has a varied clinical spectrum with underlying disease subgroups which can lead to diagnostic delay. Early diagnosis and treatment is needed to prevent potentially life threatening complications. Disclosure statement: D.P.D'C.: Consultancies: AstraZenaca, Eli Lilly, GlaxoSmithKline, Roche. P.S., C.C. and S.S. have declared no conflicts of interest.
Background: The development of dedicated patient reported outcomes (PROs) in vasculitis has received increasing attention. A better understanding of the patients' perspectives is pivotal in the development of PROs. We assessed patients' perspective of disease among cases with newly diagnosed giant cell arteritis (GCA) compared to comparator illnesses mimicking large vessel vasculitis (LVV) included in the Diagnostic and Classification Criteria in Vasculitis Study (DCVAS) database. Methods: Patient Description of Illness (PDI) forms were circulated amongst Centres participating in the DCVAS study. The PDI form records up to 10 free text severity ranked symptoms in descending order of severity, a body map to localize the sites of pain and a free text short summary of illness description. Free text was reorganized through content and thematic analysis. Results: PDI forms from 89 patients with GCA and 28 comparators (COM) were analysed. There was no difference in age and sex distribution between the two groups (mean age 70 AE 8 for GCA and 69 AE 12 for COM). The symptoms, description and frequency of the first most severe aspect of disease, including the patient's own words, is presented in Table 1 . The symptom regarded as the most severe by both groups was headache. While there were no differences in the frequency of sudden visual loss, visual symptoms were reported more commonly as the most severe feature by COM vs GCA (21% vs 8%, p ¼ 0.05). Arthralgia was more frequently reported by COM vs GCA (11% vs 1%, p ¼ 0.01). Headache was the most frequently reported symptom in both groups. Patients with GCA reported jaw claudication (37%) as the second most frequently reported symptom, while COM reported arthralgia/arthritis (32%). Shoulder neck pain was the third most important symptom in GCA (33%), while fatigue was the third most common complaint among COM (21%). Fatigue was reported as the fourth most common feature by 30% of GCA patients. Conclusion: Headache was the most frequent and most severe symptom reported by patients with GCA and comparators. However, the reported frequencies and severities of other symptoms were significantly different between the two groups. Disclosure statement: The authors have declared no conflicts of interest.
HOW COMMON ARE AUDITORY SYMPTOMS IN PATIENTS WITH GIANT CELL ARTERITIS?
Annalize Brooks, Margaret Wright, Mavis Smith and Clive Kelly Rheumatology, Queen Elizabeth Hospital, Gateshead, UNITED KINGDOM Background: It is well recognized that giant cell arteritis (GCA) can be associated with visual loss as a result of retinal artery occlusion. Far fewer clinicians and patients appreciate that deafness and vestibular dysfunction may also occur as presenting features of GCA -a feature described as occurring at a frequency of 1.3% in the limited literature to date. We undertook a detailed survey of patients with proven GCA to assess the prevalence of auditory involvement, using patients with polymyalgia rheumatica (PMR) as controls. Methods: A detailed structured questionnaire was designed to capture the presence of all auditory symptoms that might complicate presentation with GCA. Temporal associations with other symptoms of GCA were explored, as was response to steroid therapy and degree of resolution following treatment. This questionnaire was sent by post or e mail to members of the GCA Society with a proven diagnosis of GCA, and to a matched control population with proven PMR without GCA.
Results were analysed to compare the prevalence of auditory symptoms in GCA with those among controls. Results: Questionnaires were sent to 150 patients with GCA and 150 controls. Correctly completed forms were returned by 65 GCA patients (43%) and by 89 controls (63%). Mean age was 77 years in each group. Results are reported in Table 1 . Although deafness was not significantly increased, vertigo, loss of balance and tinnitus were all significantly more common among patients with GCA. In many cases symptoms responded to steroid therapy (mean dose of Prednisone 60 mg daily) within one week, although some patients were left with significant residual auditory damage. These patients reported a longer time interval between symptom onset and commencement of steroid therapy. Conclusion: Auditory involvement in GCA is underappreciated and underreported by patients and clinicians alike. The true incidence of auditory involvement may be higher than that reported in the literature to date, and includes vertigo, loss of balance and tinnitus. Most patients improve with the usual high dose steroid regime but delayed diagnosis and therapy is more likely to be associated with incomplete symptom resolution and longer term disability. reduced; only new or flaring patients showed a halo in > 4 sites. Halo size at the TA did not change significantly (average thickness 0.6 AE 0.1 mm), however, the size of AX artery halos significantly reduced from first referral (1.6 AE 0.4 mm) to follow up (1.4 AE 0.2, p ¼ 0.01) or during subsequent flares (1.4 AE 0.2, p ¼ 0.02). Conclusion: We have developed and tested a standardized methodology for CDS evaluation of GCA. CDS provides a high positive predictive value for a diagnosis of GCA in unselected patients from routine clinical practice, although prior high dose glucocorticoid therapy is likely to reduce its sensitivity. CDS allows for a significant reduction of TAB. We explored the role of CDS to detect disease flares and demonstrated a significant reduction in the extent of abnormalities, and of the size of halo of the AX arteries during follow up or flares. These findings could have a significant impact on the management of patients with suspected and confirmed GCA. Disclosure statement: The authors have declared no conflicts of interest.
A PLANNED PREDNISOLONE REGIMEN TO IMPROVE COMPLIANCE AND LOWER RELAPSE RATES IN PATIENTS WITH GIANT CELL ARTERITIS
Anoushka C. Seneviratne, Conor Graham, Karen Mills and Chetan Mukhtyar Rheumatology, Norfolk and Norwich University Hospital, Norwich, UNITED KINGDOM Background: Giant cell arteritis (GCA) is the most common form of primary systemic vasculitis. Glucocorticoids are the treatment of choice but have adverse effects in over 80% of patients. Anecdotally, a large number of patients remain on long-term prednisolone. There are no clinical trials comparing different dosing regimens. We aimed to develop an effective steroid reducing regimen to enable patients to successfully be weaned off steroids in a timely manner, and reduce the risk of relapse. Methods: Daily and cumulative prednisolone dosing from the BSR recommendations, Proven et al, and Mazlumzadeh et al were plotted on a graph. Using these results, a regimen was designed with an initial dose of 1mg/kg/day (max 60mg), reducing the dose by 20% every 4 weeks, and stopping once a dose of less than 0.5mg/day was reached (median duration 2 years). The regimen was reviewed at one year and all clinicians felt that the initial prednisolone exposure should be reduced. The regimen was redesigned using an initial daily dose of 1mg/kg of lean body mass with a logarithmic reduction over 100 weeks. Each dose was maintained for 4 weeks. The reducing regimens of 60 consecutive patients referred to a single clinic between the years 2011 and 2014 were analysed. Compliance was determined by the discontinuation of prednisolone at 100 weeks. Relapse rates were determined by the need to deviate from the planned regimen. Results: The 60 patients included 33 females, and 27 males, with a mean age of 73 years. 42 patients had either a positive temporal artery biopsy or positive temporal artery ultrasound findings, the remaining 18 were diagnosed on clinical grounds. 49 patients (82%) had relapse free discontinuation of prednisolone at 100 weeks. 11 patients [18%] relapsed when they reached an average dose of 2mg at 80 weeks after commencing prednisolone. 7 of these 11 patients had been biopsy or ultrasound positive at baseline. The 49 patients that successfully discontinued steroids received an average cumulative dose of 7.9g. Our results compare favourably to the relapse rate of 48% in one study and 92% in the control arm of another. The cumulative dose of prednisolone is comparable to both studies (6.5g and 7.8g). Conclusion: A planned corticosteroid reduction regimen designed in an evidence based manner allows the majority of patients to discontinue prednisolone at 100 weeks. We have demonstrated a much lower relapse rate compared to existing published cohorts using this regimen. Disclosure statement: The authors have declared no conflicts of interest.
FLARE RATES IN GIANT CELL ARTERITIS: A SINGLE-CENTRE LONG-TERM RETROSPECTIVE STUDY
Faidra Laskou, Gouri Koduri, Elliott Lever, Philip Stapleton and Bhaskar Dasgupta Rheumatology, Southend University Hospital NHS Trust, Westcliff, UNITED KINGDOM Background: Management of frequent flares in giant cell arteritis (GCA) is a major unmet need. However, the type, impact, and consequences of flares have been scarcely addressed. We conducted this retrospective exercise from our patients seen in the rheumatology clinic to investigate the prevalence, timing, and characteristics of flares in patients with GCA and to analyse whether flares are associated with disease-related markers, complications, tapering dose of glucocorticoid (GC) doses. Methods: We reviewed 303 patients seen with possible GCA from 2008 to 2015 with 174 diagnosed as per ACR criteria and 42 (24%) of patients presented with sight loss. Flares were defined as recurrence of signs and symptoms of GCA with or without elevation of inflammatory markers. They were classified as cranial, polymyalgia, ischemic, constitutional flares according to symptoms. We collated demographic, clinical, laboratory and imaging data with recorded time from diagnosis to steroids, duration of steroids, flare rates and types of flares. Predictors for flares were analysed using logistic regression. Results: Flares occurred in 76/174 (43. 5%). 33 (43.4%) had cranial GCA symptoms, 12 (15.6%) with ischaemic symptoms including stroke and, 20 (26.3%) with large vessel vasculitis, polymyalgic and constitutional symptoms. Some of them flared with one or more symptoms. The most frequent presenting symptoms were blurred vision, headache and jaw claudication, scalp tenderness and one patient presented with AION at follow up. One patient lost sight following disease flare. 69 (39.6%) of the total cohort were biopsy positive. More than one flare was experienced by 33 patients, 2 patients had more than 2 and one had more than 5 flares. In eight flares, ESR and CRP data were only available for 50% at the time of flare. Mean CRP was 23 at the time of relapse (range 1-127mg/L). 32 patients relapsed on GC (dose range 1-30 mg); one on TCZ and one was non-compliant. Disease recurred in 10 patients off GC and 16 had flares while attempting to wean off. Elevated ESR at baseline >100 mm/1st hour (RR 1.47, 95% CI 0.99-2.27) and sight loss (RR1.60, 95%CI 0.92-2.80) showed a trend for predicting flares but were not statistically significant. Conclusion: This study highlights that frequent flares on GC characterize the long term course of GCA. Despite the apparent initial response, long term high doses GC are associated with significant comorbidities and serious adverse events. Therapies with greater efficacy and safety with new biomarkers and imaging that help better definition of flares are urgently needed in GCA. Background: ANCA-associated vasculitis (AAV) is an organ-and lifethreatening disease. Patients present with active disease, followed by periods of remission and flare, and have impairments in mental and physical wellbeing due to disease and treatment. An international team has developed a disease-specific patient-reported outcome measure: the AAV-PRO, supported by a steering group, including four patient partners, in collaboration with the Outcome Measures in Rheumatology (OMERACT) Vasculitis Working group. Candidate questionnaire items were produced following in-depth qualitative research in the UK, US, and Canada plus cognitive interviews, extensive piloting and independent linguistic and translatability assessment. Methods: Patients with AAV were recruited from Vasculitis UK, and the Vasculitis Patient-Powered Research Network. Patients completed the 35 candidate questionnaire items, plus information about their disease, at baseline and three months (included transition item charting change). Paper copies were used in the UK and an electronic online version in the US. UK patients also completed the Euro-Qol-5D (EQ-5D-5L). In the US, a test-retest exercise was completed 3-5 days following baseline. Exploratory factor analysis (EFA) and Rasch analysis defined the underlying scale (domain) structure. The following properties were determined for each domain: convergent validity, using Pearson correlations between domain scores and the EQ-5D-5L; known groups validity, using t-tests to compare mean scores for different disease states; test-retest reliability, analysing intraclass correlation coefficients (ICC), with respondents reporting no change; and longitudinal construct validity, analysing mean change scores and effect sizes in relation to transition item responses at three months. Background: Giant cell arteritis (GCA) is one of the commonest chronic vasculitides and a common cause of blindness, representing a true medical emergency. Diagnosis of GCA is complex due to its varied presentation and management by primary and secondary care physicians, including rheumatologists and non-rheumatologists. Therefore, University Hospital Coventry and Warwickshire (UHCW) established a novel fast track GCA pathway in July 2013 to allow a streamlined process for management of GCA on the basis of specified criteria for referral Advice on urgent treatment with steroids and the role of temporal artery biopsy (TAB) and ultrasound is also stated. Uniquely there is a walk in Doppler ultrasonography service, which is
